What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2026-03-26 compared with 2025-03-31 · 1256 added, 1064 removed, 69 unchanged (97% of the section changed)

Unless otherwise provided in this Annual Report,

references to the “Company,” “we,” “us,” and “our” and similar references refer to Celcuity

Inc., a Delaware corporation.

We own various unregistered trademarks and service marks, including our corporate logo.

Solely for convenience,

the trademarks, trade names and service marks in this Annual Report, including those owned by third parties, may be referred to without

the ® , TM or SM symbols, but such references should not be construed as any indicator that the

owner of such trademarks, trade names and service marks will not assert, to the fullest extent under applicable law, their rights thereto.

We do not intend the use or display of other companies’ trademarks, trade names and service marks to imply an endorsement or sponsorship

of us by any other companies.

We are a clinical-stage biotechnology company focused

on the development of targeted therapies for the treatment of multiple solid tumor indications.

Our lead therapeutic candidate is gedatolisib,

a potent, well-tolerated, small molecule reversible inhibitor, administered intravenously, that selectively targets all Class I isoforms

of phosphatidylinositol-3-kinase (“PI3K”) and the two mechanistic targets of rapamycin (“mTOR”) sub-complexes,

mTORC1 and mTORC2.

Gedatolisib’s mechanism of action and pharmacokinetic properties are differentiated from other currently approved

and investigational therapies that target PI3K or mTOR alone or together.

We believe there is significant potential for gedatolisib to

address breast and prostate cancer tumors, and it has the potential to be used in other tumor types where the PI3K/protein kinase B (“AKT”)/mTOR

(“PAM”) pathway is either:

i) driving tumorigenesis directly;

ii) cooperating with other dysregulated signaling pathways;

or iii) a mechanism of resistance to other drug therapies.

Our initial clinical development programs for gedatolisib

are focusing on the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2

negative (“HER2-”), or HR+/HER2-, advanced or metastatic breast cancer (“ABC”), and patients with metastatic castration

resistant prostate cancer (“mCRPC”).

In January 2022, gedatolisib was granted Fast Track

designation for the treatment of patients with HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy.

Fast Track designation

is granted by the FDA for products that are intended for the treatment of serious or life-threatening diseases or conditions and which

demonstrate the potential to address an unmet medical need.

In July 2022, gedatolisib was granted Breakthrough

Therapy Designation for HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy.

Breakthrough Therapy designation is granted

by the FDA to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening

The criteria for Breakthrough Therapy designation requires preliminary clinical evidence that demonstrates the drug may have

substantial improvement on one or more clinically significant endpoints over available therapy.

In December 2022, we dosed the first patient in our

Phase 3, open-label, randomized two-part clinical trial, VIKTORIA-1.

This trial is evaluating the efficacy and safety of gedatolisib in

combination with fulvestrant with and without palbociclib in adults with HR+, HER2- advanced breast cancer who have received prior treatment

with a CDK4/6 inhibitor in combination with an aromatase inhibitor.

Two studies based on PIK3CA mutation status are included in the trial.

According to confirmed PIK3CA mutation status, patients will be manually assigned to a cohort evaluating patients who have PIK3CA wild

type (“WT”) tumors or to a cohort evaluating patients who have PIK3CA mutant (“MT”) tumors.

The two cohorts are

randomized separately.

The cohort evaluating PIK3CA WT patients completed enrollment during the fourth quarter of 2024 while the cohort

evaluating patients with PIK3CA MT (as defined below) continues to enroll patients.

In February 2024, we dosed our first patient in our

Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with mCRPC.

Initial preliminary

data for the Phase 1 portion of the trial is expected to be available by the end of the second quarter of 2025.

During the third quarter of

2024, we commenced site selection and activation activities to support a Phase 3, open-label, randomized clinical trial, VIKTORIA-2.

This trial is expected to dose its first patient in Q2 2025.

This trial will evaluate the efficacy and safety of gedatolisib plus a

CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- endocrine treatment resistant advanced breast

For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib.

Approximately 200 clinical sites in

North America, Europe, Latin America, and Asia-Pacific, including many sites included in the VIKTORIA-1 clinical

trial, will participate in the study.

The PI3K/AKT/mTOR (PAM) Pathway

Dysregulation of the PAM signaling pathway is observed

in many types of cancer, including breast and prostate cancer.

The important role the PAM pathway plays in cancer has led to significant

investment in the development of many different PI3K and mTOR inhibitors for solid tumors.

Activities associated with PI3K involve complex essential

cell regulatory mechanisms, including feedforward and feedback signaling loops.

Overactivation of the pathway is frequently present in

human malignancies and plays a key role in cancer progression.

Four catalytic isoforms of Class I PI3K preferentially mediate signal transduction

and tumor cell survival based on the type of malignancy and the genetic or epigenetic alterations an individual patient harbors.

the multiple subcellular locations, activities, and importance of the different PI3K complexes in regulating many types of cancer cell

proliferation, control of PI3K activity is an important target in cancer therapy.

mTOR is a critical effector in cell-signaling pathways

commonly dysregulated in human cancers.

The mTOR signaling pathway integrates both intracellular and extracellular signals and serves

as a central regulator of cell metabolism, growth, proliferation, and survival.

mTOR is a serine/threonine protein kinase, a downstream

effector of PI3K, and regulated by hormones, growth factors, and nutrients, that are contained in two functionally distinct protein assemblies

– mTORC1 and mTORC2.

In cancer, dysfunctional signaling leads to various constitutive activities of the mTOR complexes, making mTOR

a good therapeutic target.

Developing efficacious and well-tolerated therapies

that target this pathway has been challenging.

This reflects the inherent adaptability and complexity of the PAM pathway, where numerous

feedforward and feedback loops, crosstalk with other pathways, and compensatory pathways enable resistance to PAM pathway inhibition.

Another major hurdle for the development of PAM pathway inhibitors has been the inability to achieve optimal drug-target blockade in tumors

while avoiding undue toxicities in patients.

By targeting multiple nodes of the PAM pathway, gedatolisib

can overcome adaptive resistance mechanisms that inhibitors targeting single PI3K/AKT/mTOR nodes do not address.

As a result, we believe

gedatolisib offers distinct advantages over currently approved and investigational therapies that target PI3K or mTOR alone or together.

● Overcomes limitations of therapies that only inhibit a single Class I PI3K isoform or only one mTOR kinase complex.

Gedatolisib is a pan-class I isoform PI3K inhibitor with low

nanomolar potency for the p110α, p110β, p110γ, and p110δ isoforms.

Because gedatolisib inhibits all four PI3K isoforms

and both the mTORC1 and mTORC2 complexes, it prevents the confounding effect of isoform interaction that may occur with isoform specific

PI3K inhibitors and the confounding interaction between PI3K isoforms, AKT, and mTOR.

By contrast, node-specific inhibitors cross-activate

uninhibited sub-units due to numerous feedforward and feedback loops between the PI3K isoforms, AKT, and mTOR complexes, which in turn

induces compensatory resistance that reduces the efficacy of isoform specific PI3K, AKT, or mTORC1 inhibitors.

To compare the functional effect of inhibiting single versus

multiple PAM pathway nodes, we evaluated gedatolisib, and node-selective inhibitors for PI3Kα (alpelisib), AKT (capivasertib) and

mTORC1 (everolimus) in a panel of breast cancer cell lines using a live cell proliferation rate dose response analysis.

The results of

this analysis are presented in the table below.

Breast Cancer Cell Line Proliferation

Rate Dose Response Analysis

Average values for 14 PIK3CA MT and 14

PIK3CA WT breast cancer cell lines

Growth rate (“GR”) was assessed using 28

cell lines by measuring live cells reducing potential with Real Time-Glo MT luciferase assay before and after 72-hour drug treatment.

otherwise provided in this Annual Report, references to the “Company,” “we,” “us,” and “our”

and similar references refer to Celcuity Inc., a Delaware corporation.

We own various unregistered trademarks and service marks, including

our corporate logo.

Solely for convenience, the trademarks, trade names and service marks in this Annual Report, including those owned

by third parties, may be referred to without the ® , TM or SM symbols, but such references should

not be construed as any indicator that the owner of such trademarks, trade names and service marks will not assert, to the fullest extent

under applicable law, their rights thereto.

We do not intend the use or display of other companies’ trademarks, trade names and

service marks to imply an endorsement or sponsorship of us by any other companies.

are a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid

tumor indications.

Our lead therapeutic candidate is gedatolisib, a kinase inhibitor of the phosphatidylinositol 3-kinase

(“PI3K”), serine/threonine-protein kinase protein kinase B (“AKT”), mechanistic target of rapamycin

(“mTOR”) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2.

By targeting all

class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive inhibition of the PI3K/AKT/mTOR (“PAM”) pathway.

Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational

therapies that target PI3Kα, AKT, or mTORC1 alone or together.

Our Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib

in combination with fulvestrant, with or without palbociclib, in patients with hormone receptor-positive (HR+), human epidermal

growth factor receptor 2-negative (HER2-) (“HR+/HER2-”) advanced breast cancer (“ABC”) has completed

enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (“WT”) tumors, and has

completed enrollment of cohort 2, patients with PIK3CA mutant-type (“MT”) tumors.

Our Phase 3 clinical trial,

VIKTORIA-2, evaluating gedatolisib in combination with a cyclin-dependent kinase (“CDK”) 4/6 inhibitor and fulvestrant

as first-line treatment for patients with endocrine treatment resistant HR+/HER2- ABC is ongoing.

A Phase 1b/2 clinical trial,

CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer

(“mCRPC”), is ongoing.

January 2022, gedatolisib was granted Fast Track designation for the treatment of patients with HR+/HER2- ABC after progression on CDK4/6

Fast Track designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening

diseases or conditions and which demonstrate the potential to address an unmet medical need.

July 2022, gedatolisib was granted Breakthrough Therapy designation for HR+/HER2- ABC after progression on CDK4/6 therapy.

Therapy designation is granted by the FDA to expedite the development and regulatory review of an investigational medicine that is intended

to treat a serious or life-threatening condition.

The criteria for Breakthrough Therapy designation requires preliminary clinical evidence

that demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapy.

December 2022, we dosed the first patient in our Phase 3, open-label, randomized, two-part clinical trial, VIKTORIA-1.

This trial is evaluating

the efficacy and safety of gedatolisib in combination with fulvestrant, with and without palbociclib, in adults with HR+/HER2- ABC who

have received prior treatment with a CDK4/6 inhibitor in combination with an aromatase inhibitor.

Two studies based on PIK3CA

mutation status are included in the trial.

According to confirmed PIK3CA mutation status, patients were manually assigned either

to a cohort evaluating patients who have PIK3CA WT tumors or to a cohort evaluating patients who have PIK3CA MT tumors.

The two cohorts were randomized separately.

The cohort evaluating PIK3CA WT patients reported detailed study results in the third

and fourth quarters of 2025.

The cohort evaluating patients with PIK3CA MT tumors has completed enrollment, and topline data is

expected to be available in the second quarter of 2026.

February 2024, we dosed our first patient in our Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with

darolutamide in patients with mCRPC.

Initial preliminary data for the Phase 1 portion of the trial were reported in the fourth

quarter of 2025.

the third quarter of 2024, we commenced site selection and activation activities to support a Phase 3, open-label, randomized

clinical trial, VIKTORIA-2, designed to evaluate the efficacy and safety of gedatolisib plus a CDK4/6 inhibitor and fulvestrant as

first-line treatment for patients with HR+/HER2- endocrine treatment resistant ABC.

The first patient was dosed in July 2025.

the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib.

This multi-center, international trial enrolled 35

evaluable subjects in the safety run-in portion of the study to evaluate the safety of gedatolisib when combined with ribociclib and

The safety run-in was completed in the first quarter of 2026.

In the Phase 3 portion of the study, approximately 638

subjects are expected to be randomized and assigned to Cohort 1 ( PIK3CA WT) or Cohort 2 ( PIK3CA MT) based on their PIK3CA

Subjects in each cohort are expected to be randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and

ribociclib or palbociclib) or Arm B (fulvestrant and ribociclib or palbociclib).

We intend to provide an update on our final Phase 3 study design in the second quarter of 2026.

It is expected that approximately 200

clinical sites across North America, Europe, and Asia-Pacific will participate, including many sites included in the VIKTORIA-1

clinical trial.

August 2025, the FDA granted our request to submit our NDA for gedatolisib under the FDA’s Real-Time Oncology Review (“RTOR”)

program based on data from the PIK3CA WT cohort of the Phase 3 VIKTORIA-1 clinical trial.

We made our first NDA pre-submission

in September 2025 and completed our submission of the NDA in November 2025.

The FDA accepted our NDA on January 16, 2026, designating

it for Priority Review, with a target user fee goal date of July 17, 2026, pursuant to the Prescription Drug User Fee Act (“PDUFA”)

PI3K/AKT/mTOR (PAM) Pathway

Dysregulation

of the PAM signaling pathway is observed in many types of cancer, including breast and prostate cancer.

The important role the PAM pathway

plays in cancer has led to significant investment in the development of many different PI3K and mTOR inhibitors for solid tumors.

associated with PI3K involve complex essential cell regulatory mechanisms, including feedforward and feedback signaling loops.

Overactivation of the pathway is frequently present in human malignancies and plays a key role in cancer progression.

Four catalytic

isoforms of class I PI3K preferentially mediate signal transduction and tumor cell survival based on the type of malignancy and the

genetic or epigenetic alterations an individual patient harbors.

Due to the multiple subcellular locations, activities, and

importance of the different PI3K complexes in regulating many types of cancer cell proliferation, control of PI3K activity is an

important target in cancer therapy.

is a critical effector in cell-signaling pathways commonly dysregulated in human cancers.

The mTOR signaling pathway integrates both

intracellular and extracellular signals and serves as a central regulator of cell metabolism, growth, proliferation, and survival.

is a serine/threonine protein kinase, a downstream effector of PI3K, and regulated by hormones, growth factors, and nutrients, that are

contained in two functionally distinct protein assemblies – mTORC1 and mTORC2.

In cancer, dysfunctional signaling leads to various

constitutive activities of the mTOR complexes, making mTOR a good therapeutic target.

efficacious and well-tolerated therapies that target this pathway has been challenging.

This reflects the inherent adaptability and complexity

of the PAM pathway, where numerous feedforward and feedback loops, crosstalk with other pathways, and compensatory pathways enable resistance

to PAM pathway inhibition.

Another major hurdle for the development of PAM pathway inhibitors has been the inability to achieve optimal

drug-target blockade in tumors while avoiding undue toxicities in patients.

inhibiting multiple components of the PAM pathway, gedatolisib can overcome adaptive resistance mechanisms that inhibitors of single

PI3K/AKT/mTOR components do not address.

As a result, we believe gedatolisib offers distinct advantages over currently approved and investigational

therapies that target PI3Kα, AKT or mTORC1 alone or together.

limitations of therapies that only inhibit a single class I PI3K isoform, AKT, or one mTOR kinase complex.

is a pan-class I isoform PI3K inhibitor with low nanomolar potency for the p110α, p110β, p110γ, and p110δ

isoforms and the mTORC1 and mTORC2 complexes.

By targeting all class I PI3K isoforms and mTORC1/2, gedatolisib induces comprehensive

inhibition of the PAM pathway.

Each PI3K isoform and mTOR complex is known to preferentially affect different signal transduction

events that involve tumor cell survival, depending upon the aberrations associated with the linked pathway.

When a therapy only

inhibits a single class I PI3K isoform (e.g., alpelisib, a PI3Kα inhibitor), AKT (e.g., capivasertib, an AKT inhibitor) or

only one mTOR kinase complex (e.g., everolimus, an mTORC1 inhibitor), numerous feedforward and feedback loops between the PI3K

isoforms and mTOR complexes cross-activate the uninhibited sub-units.

This, in turn, induces compensatory resistance that reduces

the efficacy of isoform specific PI3Kα, AKT, or mTORC1 kinase inhibitors.

Inhibiting all four PI3K isoforms and both the

mTORC1 and mTORC2 complexes, as getatolisib does, thus prevents the confounding effect of isoform interaction that may occur with

isoform-specific PI3K inhibitors and the confounding interaction between PI3K isoforms, AKT, and mTOR.

compare the functional effect of inhibiting single versus multiple PAM pathway components, we evaluated gedatolisib, and component-selective

inhibitors for PI3Kα (alpelisib), AKT (capivasertib) and mTORC1 (everolimus) in a panel of breast cancer cell lines using a live

cell proliferation rate dose response analysis.

The results of this analysis are presented in the table below.

Cancer Cell Line Proliferation Rate Dose Response Analysis

values for 14 PIK3CA MT and 14 PIK3CA WT breast cancer cell lines

Growth rate (“GR”) was assessed using 28 cell lines by measuring live cells reducing potential with Real Time-Glo MT luciferase

assay before and after 72-hour drug treatment.

GR50 (concentration required to inhibit growth rate by 50%) is a measure of potency.

Max cell growth inhibition (GR at highest drug concentration

tested) is a measure of efficacy.

cell growth inhibition (GR at highest drug concentration tested) is a measure of efficacy.

et.al., npj Breast Cancer, 2024

On average, gedatolisib was 300-fold more potent than the single

node PAM inhibitors analyzed and only gedatolisib induced a significant cytotoxic effect.

In addition, gedatolisib’s potency and

efficacy was comparable in cell lines with and without PIK3CA mutations, in contrast to the single node PAM inhibitors.

● Better tolerated by patients than oral PI3K and mTOR drugs.

Gedatolisib is administered intravenously (IV) on a four-week

cycle of three-weeks-on, one-week-off, in contrast to the orally administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer

being clinically developed.

Oral pan-PI3K or PI3K/mTOR inhibitors have repeatably been found to induce significant side effects that were

not well tolerated by patients.

This typically leads to a high proportion of patients requiring dose reductions or treatment discontinuation,

average, gedatolisib was at least 300-fold more potent on average than the single component PAM inhibitors analyzed and only gedatolisib

induced a significant cytotoxic effect.

In addition, gedatolisib’s potency and efficacy was comparable in cell lines with and without

PIK3CA mutations, in contrast to the single component PAM inhibitors.

tolerated by patients than oral PI3K and mTOR drugs.

is administered intravenously (“IV”) on a four-week cycle of once a week for three weeks, then one week off, in contrast to the orally

administered pan-PI3K or dual PI3K/mTOR inhibitors that are no longer being clinically developed.

Oral pan-PI3K or PI3K/mTOR inhibitors

have repeatably been found to induce significant side effects that were not well tolerated by patients.

This typically leads to a high

proportion of patients requiring dose reductions or treatment discontinuation.

The challenging toxicity profile of these drug candidates ultimately played a significant role in the decisions to halt their development,

despite showing promising efficacy.

By contrast, gedatolisib stabilizes at lower concentration levels in plasma compared to orally administered

PI3K inhibitors, resulting in less toxicity, while maintaining concentrations sufficient to inhibit PAM pathway signaling.

Isoform-specific PI3K or mTORC1 inhibitors administered orally

were developed to reduce toxicities in patients.

While the range of toxicities associated with single-node PAM inhibitors is narrower

than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on a continuous basis still leads to challenging toxicities.

experience with the FDA approved oral PI3K-α inhibitor, alpelisib, and mTORC1 inhibitor, everolimus, illustrates the challenge.

In their Phase 3 pivotal trials, alpelisib and everolimus were found to induce hyperglycemia in 79% and 69% of patients evaluated, respectively.

In addition, 26% and 24% of patients discontinued alpelisib and everolimus, respectively, due to treatment related adverse events.

contrast, in the 103-patient dose expansion portion of the Phase 1b clinical trial with gedatolisib, only 25% of patients experienced

hyperglycemia and less than 9% discontinued treatment.

Clinical Development

As of December 31, 2024, 492 patients with solid tumors

have received gedatolisib in eight completed clinical trials.

Gedatolisib’s safety, tolerability and pharmacokinetic profile were

determined in a Phase 1 First-in-Human clinical trial.

Of the 492 patients, 129 were treated with gedatolisib as a single agent in three

By contrast, gedatolisib’s comprehensive inhibition of the PAM pathway at low nanomolar potency,

IV route of administration, and pharmacokinetic properties enables it to achieve optimal anti-proliferative effects on tumor cells without

inducing the levels of hyperglycemia, rash, and diarrhea typically associated with oral single-component inhibitors of the PAM pathway.

Isoform-specific

PI3K or mTORC1 inhibitors administered orally were developed to reduce toxicities in patients.

While the range of toxicities

associated with single-component PAM inhibitors is narrower than oral pan-PI3K or PI3K/mTOR inhibitors, administering them orally on

a continuous basis still leads to challenging toxicities.

The experience with the FDA approved oral PI3Kα inhibitor,

alpelisib, and mTORC1 inhibitor, everolimus, illustrates the challenge.

In their Phase 3 pivotal trials, alpelisib and everolimus

were found to induce hyperglycemia in 79% and 69% of patients evaluated, respectively.

In addition, 26% and 24% of patients

discontinued alpelisib and everolimus, respectively, due to treatment related adverse events.

By contrast, in the 103-patient dose

expansion portion of the Phase 1b clinical trial with gedatolisib, only 7% of patients experienced Grade 3 or 4 hyperglycemia and

less than 9% discontinued treatment.

of December 31, 2025, 1,127 patients and healthy volunteers have received gedatolisib in 12 completed or ongoing clinical trials.

Of these, 123 patients with solid tumors were treated with gedatolisib as a single agent in two clinical trials, 36 healthy volunteers

were treated in two clinical trials, and the remaining 968 patients received gedatolisib in combination with other anti-cancer agents

in eight clinical trials.

Additional patients received gedatolisib in combination with other anti-cancer agents in 10 investigator sponsored

clinical trials.

The remaining 363 patients received gedatolisib in combination with other anti-cancer agents in five clinical trials.

Additional patients received gedatolisib in combination with other anti-cancer agents in nine investigator sponsored clinical trials.

Breast Cancer Program

Breast cancer is the most prevalent cancer in women,

accounting for 30% of all female cancers and 13% of cancer-related deaths in the United States.

The National Cancer Institute estimated

that approximately 310,720 new cases of breast cancer would be diagnosed in the United States in 2024, and approximately 42,250 breast

cancer patients would die of the disease.

Four different breast cancer subtypes are currently

identified using molecular tests that determine the level of HR and HER2 expression.

The most common subtype of ABC is HR+/HER2-.

Approximately

70% of all breast cancer tumors express the estrogen receptor (“ER”), which, upon activation, regulates the expression of

various genes involved in tumor proliferation.

Despite progress in treatment strategies, metastatic HR+/HER2- breast cancer (“MBC”) remains

an incurable disease, with a median overall survival (OS) of three years and a five-year survival rate of 34%.

Three different classes of targeted therapies are

currently used to treat HR+/HER2- tumors:

endocrine-based therapies, CDK4/6 inhibitors, and PAM inhibitors.

Each of the CDK4/6 inhibitors

and PAM inhibitors are generally used to respond to the related mechanisms of resistance to endocrine therapy, namely, activation of the

CDK4/6 and PAM pathways.

Over 70% of breast cancers have direct or indirect

activation of the PAM pathway.

The upregulation of the PAM pathway promotes hormone-dependent and independent ER transcriptional activity,

which contributes to endocrine resistance, leading to tumor cell growth, survival, motility, and metabolism.

Clinical studies have demonstrated

that PAM inhibition can restore sensitivity to estrogen therapy (ET).

Additionally, the PAM pathway, like other mitogenic

pathways, can also promote the activities of cyclin D and CDK4/6 to drive proliferative cell cycling.

The available evidence indicates

that resistance to CDK4/6 inhibition in patients with HR+/HER2- advanced breast cancer is a transient adaptive mechanism, most likely

involving the PAM pathway.

This data indicates that CDK4/6 signaling may be restored in CDK4/6 resistant tumors when PAM inhibitors are

Thus, continuing CDK4/6 inhibitor treatment in combination with a PAM inhibitor in patients who progressed on their prior CDK4/6

inhibitor, would both blockade the potentially reactivated CDK4/6 pathway and prevent adaptive activation of the PAM pathway.

This suggests

the limited efficacy induced by current standard-of-care (SOC) therapies in patients who have progressed on a CDK4/6 therapy reflects

the mechanistic inadequacy of relying on partial PAM inhibition (e.g., alpelisib or everolimus) and no CDK4/6 inhibition to address this

complex disease mechanism.

We believe the complex connection between the PAM

and CDK4/6 pathways can potentially enable gedatolisib to adaptively reactivate CDK4/6 signaling that reportedly occurs in CDK4/6 resistant

tumors when the PAM pathway is comprehensively blockaded.

By re-activating CDK4/6 signaling, we believe gedatolisib can restore the therapeutic

effect of CDK4/6 inhibition when it is combined with a CDK4/6 inhibitor.

The contributory effect of a CDK4/6 inhibitor when combined with

gedatolisib would thus largely reflect the interaction between the two therapies that gedatolisib initiates.

Evidence of gedatolisib’s anti-tumor activity

in breast cancer cells was provided in a study evaluating the MCF7 xenograft model (ER+/HER2-/PIK3CA mutant), where the combination of

gedatolisib with palbociclib and fulvestrant caused 90% tumor regression with no tumor regrowth observed for more than 60 days after the

Cancer Program

cancer is the most prevalent cancer in women, accounting for 30% of all female cancers and 7% of cancer-related deaths in the United

The National Cancer Institute estimated that approximately 316,950 new cases of breast cancer would be diagnosed in the United

States in 2025, and approximately 42,170 breast cancer patients would die of the disease.

different breast cancer subtypes are currently identified using molecular tests that determine the level of HR and HER2 expression.

most common subtype of ABC is HR+/HER2-.

Approximately 70% of all breast cancer tumors express the estrogen receptor (“ER”),

which, upon activation, regulates the expression of various genes involved in tumor proliferation.

Despite progress in treatment strategies,

HR+/HER2- advanced or metastatic breast cancer remains an incurable disease, with a median overall survival (OS) of three years and a

five-year survival rate of 34%.

different classes of targeted therapies are currently used to treat HR+/HER2- tumors:

endocrine-based therapies, CDK4/6 inhibitors, and

PAM inhibitors.

Each of the CDK4/6 inhibitors and PAM inhibitors are generally used to respond to the related mechanisms of resistance

to endocrine therapy, namely, activation of the CDK4/6 and PAM pathways.

80% of breast cancers have direct or indirect activation of the PAM pathway.

The upregulation of the PAM pathway promotes hormone-dependent

and independent ER transcriptional activity, which contributes to endocrine resistance, leading to tumor cell growth, survival, motility,

and metabolism.

Clinical studies have demonstrated that PAM inhibition can restore sensitivity to endocrine therapy (ET).

Additionally,

the PAM pathway, like other mitogenic pathways, can also promote the activities of cyclin D and CDK4/6 to drive proliferative cell cycling.

The available evidence indicates that resistance to CDK4/6 inhibition in patients with HR+/HER2- ABC is a transient adaptive mechanism,

most likely involving the PAM pathway.

This data indicates that CDK4/6 signaling may be restored in CDK4/6 resistant tumors when PAM

inhibitors are applied.

Thus, continuing CDK4/6 inhibitor treatment in combination with a PAM inhibitor in patients who progressed on

their prior CDK4/6 inhibitor, would both blockade the potentially reactivated CDK4/6 pathway and prevent adaptive activation of the PAM

This suggests the limited efficacy induced by current standard-of-care (SOC) therapies in patients who have progressed on a

CDK4/6 therapy reflects the mechanistic inadequacy of relying on partial PAM inhibition (e.g., alpelisib or everolimus) and no CDK4/6

inhibition to address this complex disease mechanism.

believe the complex connection between the PAM and CDK4/6 pathways can potentially enable gedatolisib to adaptively reactivate CDK4/6

signaling that reportedly occurs in CDK4/6 resistant tumors when the PAM pathway is comprehensively inhibited.

By re-activating CDK4/6

signaling, we believe gedatolisib can restore the therapeutic effect of CDK4/6 inhibition when it is combined with a CDK4/6 inhibitor.

The contributory effect of a CDK4/6 inhibitor when combined with gedatolisib would thus largely reflect the interaction between the two

therapies that gedatolisib initiates.

of gedatolisib’s anti-tumor activity in breast cancer cells was provided in a study evaluating the MCF7 xenograft model (ER+/HER2-/PIK3CA

mutant), where the combination of gedatolisib with palbociclib and fulvestrant caused 90% tumor regression with no tumor regrowth observed

for more than 60 days after the final dose.

Layman SABCS 2021

Clinical Experience with Gedatolisib in Breast Cancer

The favorability of preliminary results from our most

recently completed clinical trial, a Phase 1b clinical trial which evaluated 138 patients with HR+/HER2- ABC, led us to focus on our initial

clinical development program on advanced breast cancer.

On January 13, 2022, gedatolisib was granted Fast

Track designation for the treatment of patients with HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy.

designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening diseases or conditions

and which demonstrate the potential to address an unmet medical need.

The designation offers the opportunity for frequent interactions

with the FDA to discuss the drug’s development plan and to ensure collection of appropriate data needed to support drug approval,

as well as eligibility for rolling submission of a New Drug Application.

On July 18, 2022, gedatolisib was granted Breakthrough

Therapy Designation for HR+/HER2- advanced breast cancer after progression on CDK4/6 therapy.

Breakthrough Therapy designation is granted

by the FDA to expedite the development and regulatory review of an investigational medicine that is intended to treat a serious or life-threatening

The criteria for Breakthrough Therapy designation require preliminary clinical evidence that demonstrates the drug may have

substantial improvement on one or more clinically significant endpoints over available therapies.

The benefits of Breakthrough Therapy

Designation include more intensive guidance from the FDA on an efficient development program, access to a scientific liaison to help accelerate

review time, and potential eligibility for priority review if relevant criteria are met.

Celcuity’s breakthrough application was

supported by data from a Phase 1b clinical trial that assessed the safety, tolerability and clinical activity of gedatolisib in combination

with palbociclib and fulvestrant in patients with HR+/HER2- advanced breast cancer whose disease progressed during treatment with a CDK4/6

therapy and an aromatase inhibitor.

Phase 1b HR+/HER2- ABC Clinical Trial Results

A Phase 1b dose-finding trial with an expansion portion

for safety and efficacy evaluated gedatolisib when added to either the standard doses of palbociclib plus letrozole or palbociclib plus

fulvestrant in patients with HR+/HER2- advanced breast cancer.

PI3K mutation status was not used as an eligibility criterion.

enrollment for the trial is complete.

A total of 138 patients with HR+/HER2- advanced breast

cancer were dosed in the clinical trial.

Four patients from this study continue to receive study treatment, as of December 31, 2024, each

of whom have received study treatment for more than five years.

● 35 patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the maximum tolerable

dose (“MTD”) of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapies.

Experience with Gedatolisib in Breast Cancer

favorability of preliminary results from a Phase 1b clinical trial (B2151009, further described below) which evaluated 138 patients

with HR+/HER2- ABC led us to focus our initial clinical development program on ABC.

January 13, 2022, gedatolisib was granted Fast Track designation for the treatment of patients with HR+/HER2- ABC after progression on

CDK4/6 therapy.

Fast Track designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening

diseases or conditions and which demonstrate the potential to address an unmet medical need.

The designation offers the opportunity for

frequent interactions with the FDA to discuss the drug’s development plan and to ensure collection of appropriate data needed to

support drug approval, as well as eligibility for rolling submission of an NDA.

July 18, 2022, gedatolisib was granted Breakthrough Therapy designation for HR+/HER2- ABC after progression on CDK4/6 therapy.

Therapy designation is granted by the FDA to expedite the development and regulatory review of an investigational medicine that is intended

to treat a serious or life-threatening condition.

The criteria for Breakthrough Therapy designation require preliminary clinical evidence

that demonstrates the drug may have substantial improvement on one or more clinically significant endpoints over available therapies.

The benefits of Breakthrough Therapy designation include more intensive guidance from the FDA on an efficient development program, access

to a scientific liaison to help accelerate review time, and potential eligibility for Priority Review if relevant criteria are met.

breakthrough application was supported by data from a Phase 1b clinical trial that assessed the safety, tolerability and clinical activity

of gedatolisib in combination with palbociclib and fulvestrant in patients with HR+/HER2- ABC whose disease progressed during treatment

with a CDK4/6 therapy and an aromatase inhibitor.

3 HR+/HER2- ABC Clinical Trial (VIKTORIA-1)

2022, we initiated VIKTORIA-1, a Phase 3, open-label, randomized clinical trial to evaluate the efficacy and safety of gedatolisib in

combination with fulvestrant with or without palbociclib in adults with HR+/HER2- ABC whose disease has progressed after prior CDK4/6

therapy in combination with an aromatase inhibitor.

This multi-center, international trial has completed enrollment of 754 subjects at

nearly 200 clinical sites across North America, Europe, Latin America, and Asia-Pacific.

The first patient was dosed in December 2022.

clinical trial is separately evaluating subjects according to their PIK3CA status.

who meet eligibility criteria and do not have confirmed PIK3CA mutations (i.e., WT) were randomly assigned (1:1:1) to receive

a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib and fulvestrant (Arm B), or fulvestrant (Arm C).

During the fourth quarter of 2024, we achieved our enrollment goal of 351 subjects who are PIK3CA WT.

We reported topline

data and detailed results for this group in the third and fourth quarters of 2025, as described below.

who meet eligibility criteria and have PIK3CA mutations (i.e., MT) were randomly assigned (3:3:1) to receive a regimen of

either gedatolisib, palbociclib, and fulvestrant (Arm D), alpelisib and fulvestrant (Arm E), or gedatolisib and fulvestrant (Arm

Enrollment of up to 350 subjects who are PIK3CA MT is ongoing.

We expect topline data for this group to be available in the second

quarter of 2026.

clinical trial primary endpoints are progression free survival (“PFS”) , per RECIST 1.1 criteria, as assessed by blinded independent central review (“BICR”).

Two primary endpoints will be evaluated in subjects who are PI3KCA WT, and one primary endpoint will be evaluated in subjects

who are PI3KCA MT.

In subjects who are PI3KCA WT, the PFS of gedatolisib in combination with palbociclib and fulvestrant

(Arm A) will be compared to fulvestrant monotherapy (Arm C), and the PFS in gedatolisib in combination with fulvestrant (Arm B) will

be compared to fulvestrant monotherapy (Arm C).

In subjects who are PI3KCA MT, the PFS of gedatolisib in combination with palbociclib

and fulvestrant (Arm D) will be compared to alpelisib combined with fulvestrant (Arm E).

subjects will receive treatment according to the assigned study arm until objective progressive disease, unacceptable toxicity, death,

or withdrawal of consent, whichever occurs first.

Subjects in Arm C will have the option to receive the treatment regimen provided in

Arm A or Arm B upon radiographically confirmed disease progression.

Subjects will be followed for adverse events, safety laboratory testing,

tumor assessment by RECIST v1.1, quality of life, and overall survival.

July 28, 2025, we announced topline data from the PIK3CA WT cohort of the VIKTORIA-1 clinical trial and on October 18, 2025, at

the European Society of Medical Oncology (“ESMO”) congress, additional efficacy and safety results from this cohort were

The key efficacy and safety data from the PIK3CA WT cohort showed:

gedatolisib triplet (gedatolisib, fulvestrant and palbociclib) demonstrated a statistically significant and clinically meaningful

improvement in PFS among patients, reducing the risk of disease progression or death by 76% compared to fulvestrant (based on a hazard

ratio [HR] of 0.24, 95% confidence interval [CI] 0.17-0.35;

The median PFS, as assessed by BICR, was 9.3 months with

the gedatolisib triplet versus 2.0 months with fulvestrant, an incremental improvement of 7.3 months.

gedatolisib doublet (gedatolisib and fulvestrant) also demonstrated a statistically significant and clinically meaningful improvement

in PFS among patients, reducing the risk of disease progression or death by 67% compared to fulvestrant (HR of 0.33, 95% CI 0.24-0.48;

The median PFS, as assessed by BICR, was 7.4 months with the gedatolisib doublet versus 2.0 months with fulvestrant,

an incremental improvement of 5.4 months.

objective response rate (“ORR”) of the gedatolisib triplet was 31% compared to 1% with fulvestrant and the median duration

of response (“DOR”) was 17.5 months.

The ORR of the gedatolisib doublet was 28.3% and the median DOR was 12.0 months.

The median DOR was not determinable for fulvestrant because there was only one objective response.

gedatolisib triplet and doublet were generally well tolerated in the trial with mostly low-grade treatment-related adverse events

The most common Grade 3 TRAEs for the gedatolisib triplet, gedatolisib doublet, and fulvestrant groups included

neutropenia (52.3%, 0%, and 0.8% of patients, respectively);

stomatitis (19.2%, 12.3%, and 0% of patients, respectively) rash (4.6%,

5.4%, and 0% of patients, respectively);

and hyperglycemia (2.3%, 2.3%, and 0% of patients, respectively).

The primary Grade 4 TRAEs

for the gedatolisib triplet and gedatolisib doublet groups were neutropenia (10.0% and 0.8%, respectively), leukopenia (0.8% in the

gedatolisib triplet group) and pneumonitis (0.8% in gedatolisib doublet group).

TRAEs led to the discontinuation of study treatment

in 2.3% of patients in the gedatolisib triplet group, 3.1% in the gedatolisib doublet group, and 0% in the fulvestrant group.

detailed results from cohort 1, PIK3CA WT cohort, established several new milestones in the history of drug development for HR+/HER2-

hazard ratios for the gedatolisib triplet and doublet are more favorable than have ever been reported by any Phase 3 trial for patients

with HR+/HER2- ABC.

7.3- and 5.4-months incremental improvements in median PFS for the gedatolisib triplet and gedatolisib doublet over fulvestrant,

respectively, are higher than have ever been reported by any Phase 3 trial for patients with HR+/HER2- ABC receiving at least their

second line of therapy.

is the first inhibitor targeting the PAM pathway to demonstrate positive Phase 3 results in patients with HR+/HER2-/ PIK3CA

WT ABC whose disease progressed on or after treatment with a CDK4/6 inhibitor.

median DOR and incremental ORR improvement relative to control for the gedatolisib triplet and doublet are the highest reported for

an endocrine therapy-based regimen in 2L HR+/HER2- ABC.

December 2025, updated efficacy and safety results from the Phase 3 VIKTORIA-1 PIK3CA WT cohort were presented at the 2025 San Antonio

Breast Cancer Symposium including patient sub-group analyses, safety analyses and patient reported outcomes for well-being measures.

For patients enrolled in the U.S., Canada, Western Europe,

and Asia Pacific, median PFS was 16.6 months with the gedatolisib triplet and 7.1 months with the gedatolisib doublet versus 1.9 months

for fulvestrant (HR=0.14;

Both gedatolisib regimens delayed time to definitive deterioration

versus fulvestrant according to patient reported outcomes for well-being measures that included mobility, self-care, usual activities,

pain/discomfort, and anxiety/depression (the EQ-5D-5L score).

The median time to definitive deterioration was 23.7 months (HR=0.39;

p = 0.0003) for patients treated with the gedatolisib triplet and not reached for the gedatolisib doublet (HR=0.37;

p = 0.0003) versus 4.0 months for fulvestrant.

Additionally, for the first eight cycles of treatment, the patients’ assessment of their well-being remained

stable relative to their assessment prior to starting treatment with gedatolisib.

median PFS benefit of the gedatolisib triplet and doublet compared to fulvestrant was consistent across subgroups with the gedatolisib

triplet showing higher clinical benefit in nearly all subgroups compared to the gedatolisib doublet, particularly for patients who were

pre/perimenopausal, endocrine therapy resistant, or had visceral metastases.

For patients enrolled in the United States and Canada, median

PFS was 19.3 months (HR=0.13;

0.07-0.29) for the gedatolisib triplet and 14.9 months (HR=0.35;

0.17-0.76) for the gedatolisib

these results, the gedatolisib regimens represent a potential new standard of care for patients with HR+/HER2-, PIK3CA WT ABC

whose disease progressed on or after treatment with a CDK4/6 inhibitor.

from cohort 2 of the VIKTORIA-1 Phase 3 clinical trial, the PIK3CA MT cohort, are expected to be available in the second quarter

B2151009 Phase

1b HR+/HER2- ABC Clinical Trial

Phase 1b dose-finding trial with an expansion portion for safety and efficacy evaluated gedatolisib when added to either the standard

doses of palbociclib plus letrozole or palbociclib plus fulvestrant in patients with HR+/HER2- ABC.

PI3K mutation status was not used

as an eligibility criterion.

Patient enrollment for the trial is complete.

total of 138 patients with HR+/HER2- ABC were dosed in the clinical trial.

Four patients from this study continue

to receive study treatment, as of December 31, 2025, each of whom has received study treatment for more than six years.

patients were enrolled in two dose escalation arms to evaluate the safety and tolerability and determine the maximum tolerable dose

(“MTD”) of gedatolisib when used in combination with the standard doses of palbociclib and endocrine therapies.

was determined to be 180 mg administered intravenously once weekly.

● 103 patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus

palbociclib and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical

patients were enrolled in one of four expansion arms (A, B, C, D) to determine if the triplet combination of gedatolisib plus palbociclib

and letrozole or gedatolisib plus palbociclib and fulvestrant produced a superior objective response (OR), compared to historical

control data of the doublet combination (palbociclib plus endocrine therapy).

All patients received gedatolisib in combination with standard

doses of palbociclib and endocrine therapy (either letrozole or fulvestrant).

In Arms A, B, and C, patients received an intravenous dose

of 180 mg of gedatolisib once weekly.

In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on a four-week cycle of

three-weeks-on, one-week-off.

Objective response was determined using Response Evaluation Criteria in Solid Tumors v1.0, or RECIST v1.0.

All patients received gedatolisib in combination with

standard doses of palbociclib and endocrine therapy (either letrozole or fulvestrant).

In Arms A, B, and C, patients received an

intravenous dose of 180 mg of gedatolisib once weekly.

In Arm D, patients received an intravenous dose of 180 mg of gedatolisib on

a four-week cycle of three-weeks-on, one-week-off.

Objective response was determined using Response Evaluation Criteria in Solid

Tumors v1.0, or RECIST v1.0.

ABC with progression and no prior endocrine-based systemic therapy or a CDK4/6 inhibitor in the metastatic setting.

First-line endocrine-based therapy for advanced disease (CDK4/6 treatment naive).

ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting, with no prior

therapy with any CDK inhibitor.

endocrine-based therapy for advanced disease (CDK4/6 treatment naive).

ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting, with no prior therapy

with any CDK inhibitor.

Second- or third-line endocrine-based therapy for metastatic disease.

ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following

prior therapy with a CDK inhibitor.

ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following prior

therapy with a CDK inhibitor.

Second- or third-line endocrine-based therapy for advanced disease.

ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following

prior therapy with a CDK inhibitor.

ABC with progression during one or two prior endocrine-based systemic therapies in the advanced setting and following prior

therapy with a CDK inhibitor.

Second- or third-line endocrine-based therapy for advanced disease.

● For the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, the objective response rate (“ORR”)

in aggregate among patients with evaluable tumors was 63%.

● Best responses, as measured by RECIST v1.0, are shown in the following chart for Arm A (1 st line patients) and Arm D (2 nd /3 rd

line patients who received Phase 3 dosing regimen).

The dotted line represents the cutoff for partial response (PR), defined as a 30%

reduction from the baseline tumor assessment.

the 103 patients enrolled in the expansion portion of the Phase 1b clinical trial, the ORR in aggregate among patients with evaluable

tumors was 63%.

responses, as measured by RECIST v1.0, are shown in the following chart for Arm A (1 st line patients) and Arm D

(2 nd /3 rd line patients who received the VIKTORIA-1 Phase 3 trial dosing regimen).

The dotted line represents

the cutoff for partial response (PR), defined as a 30% reduction from the baseline tumor assessment.

Layman SABCS 2021

● Safety analysis:

○ For all arms in aggregate, all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event.

and 4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia (63%), stomatitis (27%) and rash (20%).

all arms in aggregate, all patients experienced at least one Grade 1 or Grade 2 treatment-emergent adverse event.

The Grade 3 and

4 treatment-emergent adverse events occurring in at least 20% of patients were neutropenia (63%), stomatitis (27%) and rash (20%).

Neutropenia is a known class effect of CDK4/6 inhibitors.

Stomatitis was reversible in most patients with a steroidal mouth rinse.

grades of treatment-related adverse events related to hyperglycemia were reported in 22% of patients;

Grade 3 or 4 hyperglycemia was reported

in 7% of patients.

All grades of treatment-related adverse events related to hyperglycemia were reported in 22% of patients;

Grade 3 or 4 hyperglycemia

was reported in 7% of patients.

Gedatolisib was discontinued in less than 9% of patients.

○ For the patients in Arm D, who received the Phase 3 dosing schedule, Grade 3 and 4 treatment-emergent adverse events occurring in

at least 20% of patients were neutropenia (67%), leukopenia (22%), and stomatitis (22%).

the patients in Arm D, who received the Phase 3 dosing schedule, Grade 3 and 4 treatment-emergent adverse events occurring in at

least 20% of patients were neutropenia (67%), leukopenia (22%), and stomatitis (22%).

All grades of treatment-related adverse events

1 unchanged sentence

Grade 3 or 4 hyperglycemia were reported in 7% of patients.

Gedatolisib was

discontinued in 4% of patients.

● Best overall response data for each arm is presented in the table below:

Total Expansion Arms

was discontinued in 4% of patients.

overall response data for each arm is presented in the table below:

Total Expansion Arms (N=103)

Prior Therapy

11 unchanged sentences

PFS at 12 months

(1) ORR represents PR, except in Arm A, which had 1 CR = Complete

ORR represents PR, except in Arm A, which had 1 CR = Complete response.

Responses per RECIST 1.1;

2 unchanged sentences

1L = first line, 2L = second line;

mos = months;

NR = not reached;

ORR = objective response rate;

PFS, progression free survival

PFS = progression free

al, Lancet Oncol., 2024

Phase 3 HR+/HER2- ABC Clinical Trial (VIKTORIA-1)

In 2022, we initiated VIKTORIA-1, a Phase 3, open-label,

randomized clinical trial to evaluate the efficacy and safety of gedatolisib in combination with fulvestrant with or without palbociclib

in adults with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 therapy in combination with an aromatase

This multi-center, international trial is expected to enroll approximately 701 total subjects at more than 200 clinical sites

across North America, Europe, Latin America, and Asia-Pacific.

The first patient was dosed in December 2022.

The clinical trial enables separate evaluation of

subjects according to their PIK3CA status.

● Subjects who meet eligibility criteria and do not have confirmed PIK3CA mutations (i.e., WT) are randomly assigned (1:1:1)

to receive a regimen of either gedatolisib, palbociclib, and fulvestrant (Arm A), gedatolisib and fulvestrant (Arm B), or fulvestrant

During the fourth quarter of 2024, we achieved our enrollment goal of 351 subjects who are PIK3CA WT.

We expect topline data

for this group to be available in Q2 2025.

● Subjects who meet eligibility criteria and have PIK3CA mutations (i.e., MT) are randomly assigned (3:3:1) to receive a regimen

of either gedatolisib, palbociclib, and fulvestrant (Arm D), alpelisib and fulvestrant (Arm E), or gedatolisib and fulvestrant (Arm F).

Enrollment of up to 350 subjects who are PIK3CA MT is ongoing.

We expect topline data for this group to be available in the fourth quarter

The clinical trial primary endpoints are progression

free survival (“PFS”), per RECIST 1.1 criteria, as assessed by blinded independent central review (“BICR”).

primary endpoints will be evaluated in subjects who are PI3KCA WT, and one primary endpoint will be evaluated in subjects who are PI3KCA

In subjects who are PI3KCA WT, the PFS of gedatolisib in combination with palbociclib and fulvestrant (Arm A) will be compared to

fulvestrant monotherapy (Arm C), and the PFS in gedatolisib in combination with fulvestrant (Arm B) will be compared to fulvestrant monotherapy

In subjects who are PI3KCA MT, the PFS of gedatolisib in combination with palbociclib and fulvestrant (Arm D) will be compared

to alpelisib combined with fulvestrant (Arm E).

All subjects will receive treatment according to the

assigned study arm until objective progressive disease, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first.

Subjects in Arm C will have the option to receive the treatment regimen provided in Arm A or Arm B upon radiographically confirmed disease

Subjects will be followed for adverse events, safety laboratory testing, tumor assessment by RECIST v1.1, quality of life,

and overall survival.

Phase 3 HR+/HER2- ABC Clinical Trial (VIKTORIA-2)

During the third quarter of 2024, we initiated site

selection and activation activities to support a Phase 3, open-label, randomized clinical trial to evaluate the efficacy and safety of

gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer that is

endocrine treatment resistant (VIKTORIA-2).

results from the Phase 1b portion of the clinical trial were presented at the ESMO congress in October 2025.

The analyses reported efficacy

data from patients who were treated with the same drug regimen being evaluated in the VIKTORIA-1 study, gedatolisib combined with fulvestrant

and palbociclib.

This included patients from Escalation Arm B and Expansion Arms B, C and D of the Phase 1b study.

described above, patients in Escalation Arm B and Expansion Arms B and C received a 180 mg dose of gedatolisib once weekly (“weekly

Patients in Expansion Arm D received a 180 mg dose of gedatolisib on days 1, 8, and 15 of a four-week cycle (“intermittent

dose”), which is the same dose regimen patients in the VIKTORIA-1 study receive.

The proportion of patients who received the intermittent

dose of gedatolisib was 37% for those with PIK3CA MT tumors and 25% for those with PIK3CA WT tumors.

The proportion of

patients who received prior treatment with a CDK4/6 inhibitor was 73% for those with PIK3CA WT tumors, and 71% for those with

PIK3CA MT tumors.

PFS and the ORR were assessed in sub-groups of patients according to their PIK3CA status (Table 1).

For all analyzed patients

with PIK3CA MT tumors (n=30), median PFS was 14.6 months and the ORR in response evaluable patients was 48%.

Median PFS was 19.7

months and the ORR was 64% in patients with PIK3CA MT tumors who received the intermittent dose of gedatolisib used in the VIKTORIA-1

For patients with PIK3CA WT tumors (n=60), median PFS was 9.0 months and the ORR in response evaluable patients was 41%.

Median PFS was 9.1 months and the ORR was 53% in patients with PIK3CA WT tumors who received the intermittent dose of gedatolisib

used in the VIKTORIA-1 study.

Efficacy Analysis of Phase 1b Patients Treated with Gedatolisib Plus Palbociclib Plus Fulvestrant

Intermittent Dose

Intermittent dose

Median PFS (months)

3 HR+/HER2- ABC Clinical Trial (VIKTORIA-2)

July 2025, we dosed the first patient in VIKTORIA-2, a Phase 3, multi-center, open-label, randomized, clinical trial designed to

evaluate the efficacy and safety of gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with

HR+/HER2- endocrine treatment resistant ABC.

For the CDK4/6 inhibitor, investigators may choose either ribociclib or palbociclib.

multi-center, international trial is expected to enroll approximately 12–36 evaluable subjects in the safety run-in portion of the

study to evaluate the safety of gedatolisib when combined with ribociclib and fulvestrant.

In the Phase 3 portion of the study, approximately

638 subjects will be randomized and assigned to Cohort 1 (“PIK3CA WT”) or Cohort 2 (“PIK3CA MT”) based on their PIK3CA status.

Subjects in each cohort will be randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and ribociclib or palbociclib)

or Arm B (fulvestrant and ribociclib or palbociclib).

It is expected that approximately 200 clinical sites across North America, Europe,

Latin America, and Asia-Pacific will participate.

The first patient is expected to be dosed in the second quarter of 2025.

The clinical trial primary endpoints for this study

are PFS, per RECIST 1.1 criteria, as assessed by BICR.

The statistical analyses of Cohort 1 and 2 are independent of the other.

cohort, the PFS of gedatolisib in combination with fulvestrant and either palbociclib or ribociclib (Arm A) will be compared to fulvestrant

combined with either palbociclib or ribociclib (Arm B).

Prostate Cancer Program

In the United States, prostate cancer is the second

leading cause of cancer death in men.

Current estimates predict that one in eight men will be diagnosed with prostate cancer in his lifetime.

The National Cancer Institute estimates that in 2024 there will be over 299,000 new cases of prostate cancer in the United States and

approximately 35,250 deaths from the disease.

Although approximately 69% of patients are diagnosed with localized prostate cancer, about

8% of patients present with metastatic disease with a 5-year survival rate of 37%.

Androgen deprivation therapy (“ADT”) via

medical or surgical castration has been the mainstay treatment for metastatic prostate cancer.

However, prostate cancer cells develop

resistance to ADT and progress to castration resistance, leading to poor prognosis and a median overall survival of about three to five years.

Men with mCRPC have a poor prognosis and a predicted

survival rate of fewer than two years from the initial time of progression.

Treatment options for prostate cancer depend on many different

factors, including the stage of the cancer.

Castration-resistant prostate cancer is defined by disease progression despite ADT and is

often indicated by rising levels of PSA.

Current standard of care for men with castration-resistant prostate cancer provides that patients

should initially receive a combination of ADT and either abiraterone, which works by decreasing androgen levels, or enzalutamide, which

works by blocking androgen binding to androgen receptors (“AR”).

If the disease progresses despite these second-generation

hormonal therapies, chemotherapy is considered the next treatment option.

Treatment with chemotherapy is generally postponed for as long

as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased

risk of infections.

Preclinical studies have demonstrated a potential

association between the PAM pathway and AR signaling in prostate cancer cells developing resistance to ADT.

In these studies, the AR and

PAM pathways were shown to cross-regulate each other.

This is similar to the relationship demonstrated in breast cancer with the estrogen

receptor pathway and the PAM pathway.

Additionally, 70% - 100% of mCRPC tumors have PAM related pathway alterations.

Several clinical studies have shown promising results

by inhibiting the PAM pathway in combination with an AR inhibitor.

In separate Phase 2 and Phase 3 trials, the AKT inhibitor, ipatasertib,

showed improvement in radiographic PFS (“rPFS”) in patients with mCRPC and tumors with phosphatase and tensin homolog (“PTEN”)

loss when ipatasertib was combined with the AR inhibitor, abiraterone, versus abiraterone alone.

In a Phase 2 trial, the pan-PI3K inhibitor,

samotolisib, reported median rPFS of 10.2 when combined with enzalutamide versus 5.5 months for enzalutamide alone.

Evidence of gedatolisib’s in vivo activity in

prostate cancer was provided in a study evaluating the 22RV-1, PC3, and C4-2 prostate cancer xenograft models.

As seen in the figures

below, gedatolisib induced greater than 80% tumor growth inhibition, regardless of the xenograft model’s sensitivity to the AR inhibitor,

enzalutamide and the cell lines’ PTEN or AR status.

In addition, gedatolisib combined with enzalutamide induced significantly greater

tumor growth inhibition than enzalutamide alone in the enzalutamide sensitive model (“C4-2”).

This multi-center, international trial enrolled 35 evaluable subjects in the safety run-in portion of the study to evaluate the

safety of gedatolisib when combined with ribociclib and fulvestrant.

The safety run-in was completed in the first quarter of 2026.

In the Phase 3 portion of the study, approximately 638 subjects are expected to be randomized and assigned to Cohort 1

( PIK3CA WT) or Cohort 2 ( PIK3CA MT) based on their PIK3CA status.

Subjects in each cohort are expected to be

randomized on a 1:1 basis to either Arm A (gedatolisib with fulvestrant and ribociclib or palbociclib) or Arm B (fulvestrant and

ribociclib or palbociclib).

We intend to provide an update on our final Phase 3 study design in the second quarter of 2026.

It is expected that approximately 200 clinical sites across North America, Europe, and

Asia-Pacific will participate, including many sites included in the VIKTORIA-1 clinical trial.

Cancer Program

the United States, prostate cancer is the second leading cause of cancer death in men.

Current estimates predict that one in eight men

will be diagnosed with prostate cancer in his lifetime.

The National Cancer Institute estimated that in 2025 there would be over 313,780

new cases of prostate cancer in the United States and approximately 35,770 deaths from the disease.

Although approximately 69% of patients

are diagnosed with localized prostate cancer, about 8% of patients present with metastatic disease with a 5-year survival rate of 38%.

Androgen deprivation therapy (“ADT”) via medical or surgical castration has been the mainstay treatment for metastatic prostate

However, prostate cancer cells develop resistance to ADT and progress to castration resistance, leading to poor prognosis and

a median overall survival of about three to five years.

with mCRPC have a poor prognosis and a predicted survival rate of fewer than two years from the initial time of progression.

options for prostate cancer depend on many different factors, including the stage of the cancer.

Castration-resistant prostate cancer

is defined by disease progression despite ADT and is often indicated by rising levels of PSA.

Current standard of care for men with castration-resistant

prostate cancer provides that patients should initially receive a combination of ADT and either abiraterone, which works by decreasing

androgen levels, or enzalutamide, which works by blocking androgen binding to androgen receptors (“AR”).

If the disease progresses

despite these second-generation hormonal therapies, chemotherapy is considered the next treatment option.

Treatment with chemotherapy

is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea,

decreased mental capacity and increased risk of infections.

studies have demonstrated a potential association between the PAM pathway and AR signaling in prostate cancer cells developing resistance

In these studies, the AR and PAM pathways were shown to cross-regulate each other.

This is similar to the relationship demonstrated

in breast cancer with the estrogen receptor pathway and the PAM pathway.

Additionally, 70% - 100% of mCRPC tumors have PAM related pathway

clinical studies have shown promising results by inhibiting the PAM pathway in combination with an AR inhibitor.

In separate Phase 2

and Phase 3 trials, the AKT inhibitor, ipatasertib, showed improvement in radiographic PFS (“rPFS”) in patients with mCRPC

and tumors with phosphatase and tensin homolog (“PTEN”) loss when ipatasertib was combined with the AR inhibitor, abiraterone,

versus abiraterone alone.

In a Phase 2 trial, the pan-PI3K inhibitor, samotolisib, reported median rPFS of 10.2 when combined with enzalutamide

versus 5.5 months for enzalutamide alone.

of gedatolisib’s in vivo activity in prostate cancer was provided in a study evaluating the 22RV-1, PC3, and enzalutamide sensitive

model (“C4-2”) prostate cancer xenograft models.

As seen in the figures below, gedatolisib induced greater than 80% tumor

growth inhibition, regardless of the xenograft model’s sensitivity to the AR inhibitor, enzalutamide and the cell lines’

PTEN or AR status.

In addition, gedatolisib combined with enzalutamide induced significantly greater tumor growth inhibition than enzalutamide

alone in the C4-2.

Sen, ASCO-GU, 2023

Phase 1b/2 mCRPC Clinical Trial (CELC-G-201)

We received approval from the FDA in mid-2023 to proceed

with the clinical development of gedatolisib in combination with Nubeqa® (darolutamide), an approved androgen receptor inhibitor,

for the treatment of patients with mCRPC.

We have since initiated a Phase 1b/2 clinical trial (CELC-G-201) that will enroll up to 54 participants

with mCRPC who progressed after treatment with an AR inhibitor.

We dosed our first patient in this trial in February 2024.

In the Phase 1b portion of the clinical trial, we

enrolled 36 participants randomly assigned to receive 600 mg darolutamide combined with either 120 mg gedatolisib in Arm 1 or 180 mg gedatolisib

An additional 12 participants will then be enrolled in the Phase 2 portion of the study at the recommended phase 2 dose (“RP2D”)

level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.

The primary objectives of the Phase 1b portion of

the trial include assessment of the safety and tolerability of gedatolisib in combination with darolutamide and determination of the recommended

Phase 2 dose of gedatolisib.

The primary objective of the Phase 2 portion of the trial is to assess the rPFS at six months of patients

who received the RP2D.

Pfizer License Agreement

In April 2021, we entered into a license agreement

(“the Gedatolisib License Agreement”) with Pfizer pursuant to which we acquired exclusive (including as to Pfizer) worldwide

sublicensable rights to research, develop, manufacture, and commercialize gedatolisib for the treatment, diagnosis and prevention of all

Pursuant to the Gedatolisib License Agreement, we are obligated to use commercially reasonable efforts to develop and seek regulatory

approval for at least one product in the U.S.

and if regulatory approval is obtained, to commercialize such product in the U.S.

least one international major market.

We paid Pfizer a $5.0 million upfront fee upon execution

of the Gedatolisib License Agreement and issued to Pfizer $5.0 million of our common stock.

We are also required to make milestone payments

to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $335.0 million.

We will pay Pfizer

tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, that may be subject to deductions for expiration

of valid claims, amounts due under third-party licenses and generic competition.

Unless earlier terminated, the Gedatolisib License Agreement

will expire upon the expiration of all royalty obligations.

1b/2 mCRPC Clinical Trial (CELC-G-201)

received approval from the FDA in mid-2023 to proceed with the clinical development of gedatolisib in combination with Nubeqa ®

(darolutamide), an approved androgen receptor inhibitor, for the treatment of patients with mCRPC.

We have since initiated a Phase 1b/2

clinical trial (CELC-G-201) that will enroll up to 54 participants with mCRPC who progressed after treatment with an AR inhibitor.

dosed our first patient in this trial in February 2024.

The primary objectives of the Phase 1b portion of the trial include assessment of the safety and tolerability of gedatolisib in combination

with darolutamide and determination of the recommended Phase 2 dose (“RP2D”) of gedatolisib.

The primary objective of the

Phase 2 portion of the trial is to assess the radiographic PFS at six months of patients who received the RP2D.

the Phase 1b portion of the clinical trial, we enrolled 38 participants randomly assigned to receive 600 mg of darolutamide twice

daily combined with either 120 mg of gedatolisib in Arm 1 or 180 mg of gedatolisib in Arm 2.

In both arms, gedatolisib was

administered once weekly for three weeks, then one week off.

Additionally, all patients received prophylactic treatment for

On June 30, 2025, we announced preliminary data for the CELC-G-201 Phase 1b trial, utilizing a May 30, 2025 data cut-off.

Based on these

data, we amended the clinical trial protocol to enable exploration of additional doses in the Phase 1b portion of this clinical trial

to determine the RP2D.

Once RP2D is determined, an additional 12 participants will then be enrolled in the Phase 2 portion of the study

at the RP2D level to enable evaluation of 30 participants treated with the RP2D of gedatolisib.

On October 18,

2025, at the ESMO congress, we presented updated clinical results for the CELC-G-201 Phase 1b trial based on an August 15, 2025 data

Among the 38 patients enrolled, 61% had received

one line of prior systemic therapy and 39% had received at least two or more lines of prior therapy.

clinical results from the Phase 1 portion of the clinical trial were presented at the ESMO congress in October 2025.

The Phase 1 data

set utilized an August 15, 2025 data cut-off.

Median duration of follow-up was 9.0 months.

six-month rPFS rate and median rPFS for patients from both arms combined was 67% and 9.1 months, respectively.

For patients treated with

120 mg gedatolisib, the six-month rPFS rate was 74% and median rPFS was 9.5 months.

For patients treated with 180 mg gedatolisib, the

six-month rPFS rate was 61% and the median rPFS was 7.4 months.

combination of gedatolisib and darolutamide was generally well tolerated in the trial with mostly low-grade TRAEs.

No dose limiting toxicities

were observed in either arm.

The only Grade 3 TRAEs for patients from both arms combined included rash (5.3%), stomatitis (2.6%), and

pruritus (2.6%);

no Grade 3 hyperglycemia was reported.

Additionally, no Grade 4 or 5 TRAEs were observed, and no patients discontinued

study treatment due to a TRAE.

the amended Phase 1/1b portion of the clinical trial, up to six patients are planned to be enrolled in each of three arms and treated

with different doses.

Upon completion of Phase 1, up to an additional 40 patients will be randomly assigned to up to four Phase 1b cohorts

to determine the RP2D.

Dose levels will be selected based on the results from the Phase 1 clinical

In the Phase 2 dose expansion study, which will include subjects from the Phase 1/1b clinical trial, up to 18 additional subjects

will be enrolled to achieve a total of approximately 30 subjects treated with the RP2D.

All patients will also receive standard doses

of darolutamide.

Investigator-Sponsored

an investigator-sponsored Phase 2 clinical trial, 44 patients with HER2+/ PIK3CA mutated metastatic breast cancer were treated

with gedatolisib plus standard doses of trastuzumab-pkrb.

No prophylaxis for stomatitis was administered.

The median number of prior

anti-HER2 therapies enrolled patients received in the metastatic setting was four or more;

86% of patients had received at least three

prior anti-HER2 therapies.

The data cut-off was February 10, 2025.

efficacy and safety results, as presented at the American Society of Clinical Oncology meeting in June 2025, showed:

ORR among all patients enrolled was 43%.

PFS was 6.0 months (95% CI, 5.0-7.7).

overall survival was 24.7 months (95% CI;

patients discontinued gedatolisib due to a treatment-related AE.

(2.3%) patient experienced Grade 3 hyperglycemia.

investigator sponsored trial has been initiated in collaboration with the Dana-Farber Cancer Institute and Massachusetts General Hospital

to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancer.

Gedatolisib License Agreement

April 2021, we entered into a license agreement (the “Gedatolisib License Agreement”) with Pfizer pursuant to which we acquired

exclusive (including as to Pfizer) worldwide sublicensable rights to research, develop, manufacture, and commercialize gedatolisib for

the treatment, diagnosis and prevention of all diseases.

Pursuant to the Gedatolisib License Agreement, we are obligated to use commercially

reasonable efforts to develop and seek regulatory approval for at least one product in the U.S.

and if regulatory approval is obtained,

to commercialize such product in the U.S.

and at least one international major market.

paid Pfizer a $5.0 million upfront fee upon execution of the Gedatolisib License Agreement and issued 349,406 shares of our common

stock to Pfizer pursuant to an Equity Grant Agreement.

We are also required to make milestone payments to Pfizer upon achievement of

certain development and commercial milestone events, including a $5.0 million milestone payment we made in January 2026 following

FDA acceptance of our NDA submission, up to an aggregate of $335.0 million.

We will pay Pfizer tiered royalties on sales of

gedatolisib at percentages ranging from the low to mid-teens, that may be subject to deductions for expiration of valid claims,

amounts due under third-party licenses and generic competition.

Unless earlier terminated, the Gedatolisib License Agreement will

expire upon the expiration of all royalty obligations.

The royalty period will expire on a country-by-country basis upon the later

of (a) 12 years following the date of First Commercial Sale of such Product in such country, (b) the expiration of all regulatory or data

exclusivity in such country for such Product, or (c) the date upon which the manufacture, use, sale, offer for sale or importation of

such Product in such country would no longer infringe, but for the license granted herein, a Valid Claim of a Licensed Patent Right.

terms in this paragraph have the meanings set forth in the Gedatolisib License Agreement.

We have the right to terminate the Gedatolisib License

Agreement for convenience upon 90 days’ prior written notice.

Pfizer may not terminate the agreement for convenience.

or Pfizer may terminate the Gedatolisib License Agreement if the other party is in material breach and such breach is not cured within

the specified cure period.

In addition, either we or Pfizer may terminate the Gedatolisib License Agreement in the event of specified

insolvency events involving the other party.

Manufacturing

We rely on third parties to manufacture gedatolisib.

We have entered into agreements with contract manufacturing organizations (“CMOs”), to produce the drug substance gedatolisib,

and produce, package and distribute finished drug product for clinical supply.

We require all of our CMOs to conduct manufacturing activities

in compliance with applicable laws including current good manufacturing practice (“cGMP”), requirements.

We anticipate that

these CMOs will have the capacity to support both clinical supply and commercial-scale production, and we have started negotiating agreements

at this time to cover commercial production.

We may also elect to enter into agreements with other CMOs to manufacture supplies of drug

substance and finished drug product.

Sales and Marketing

If any of our product candidates are approved, we

intend to market and commercialize them in the U.S.

and select international markets, either alone or in partnership with others.

patients are primarily treated by medical, surgical, or radiation oncologists, and we believe they can be reached with a targeted sales

Competition for Gedatolisib

The pharmaceutical industry is characterized by rapid

evolution of technologies and intense competition.

While we believe that our product candidates, technology, knowledge, experience, intellectual

property, and scientific resources provide us with competitive advantages, we face competition from major pharmaceutical and biotechnology

companies, academic institutions, governmental agencies and public and private research institutions, among others.

Any product candidates

that we successfully develop and commercialize will compete with approved treatment options, including off-label therapies, and new therapies

that may become available in the future.

Key considerations that would impact our ability to effectively compete with other therapies

include the efficacy, safety, method of administration, cost, level of promotional activity and intellectual property protection of our

Many of the companies against which we may compete have significantly greater financial resources and expertise than we do in

research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing

approved products.

There are several PI3K, AKT, and mTOR inhibitors approved

by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca plc, Itovebi from F.

Hoffmann-La Roche Ltd, COPIKTRA

from Verastem, Inc., and ZYDELIG from Gilead Sciences, Inc.

We are aware that other companies are, or may be, developing products for

this indication, including BridgeBio Pharma Inc., Eli Lilly and Company, Kazia Therapeutics Limited, Relay Therapeutics, Inc., Revolution

Medicines Inc., and Takeda Pharmaceutical Company Limited.

There may be additional companies with programs suitable for addressing these

patient populations that could be competitive with our efforts but that have not yet disclosed specific clinical development plans.

or early-stage companies, including oncology-focused therapeutics companies, may also prove to be significant competitors, particularly

through collaborative arrangements with large and established companies.

These companies may also compete with us in recruiting and retaining

qualified scientific and management personnel, establishing clinical trial sites, enrolling patients in clinical trials and acquiring

technologies complementary to, or necessary for, our programs.

The availability of reimbursement from government and private payors will

also significantly impact the pricing and competitiveness of our products.

Our competitors may obtain FDA or other regulatory approvals

for their products more rapidly than we may obtain approvals for our product candidates, which could result in our competitors establishing

a strong market position before we are able to commercialize our product candidates.

We founded our company to develop our proprietary

CELsignia diagnostic platform and relied on the capability of this technology to identify our lead drug candidate, gedatolisib.

characterizes the specific activity of various oncogenic signaling pathways, including the PAM pathway, in living patient tumor cells.

As previously disclosed, we made the decision to focus on the clinical development of gedatolisib and minimize our activities to support

development of CELsignia.

Intellectual Property

Our success depends in part on our ability to obtain

and maintain proprietary protection for our product candidates, manufacturing and process discoveries and other know-how, to operate without

of (a) 12 years following the date of First Commercial Sale of such Product in such country, (b) the expiration of all regulatory or

data exclusivity in such country for such Product, or (c) the date upon which the manufacture, use, sale, offer for sale or

importation of such Product in such country would no longer infringe, but for the license granted herein, a Valid Claim of a

Licensed Patent Right.

Capitalized terms in this paragraph have the meanings set forth in the Gedatolisib License

have the right to terminate the Gedatolisib License Agreement for convenience upon 90 days’ prior written notice.

Pfizer may not

terminate the agreement for convenience.

Either we or Pfizer may terminate the Gedatolisib License Agreement if the other party is in

material breach and such breach is not cured within the specified cure period.

In addition, either we or Pfizer may terminate the Gedatolisib

License Agreement in the event of specified insolvency events involving the other party.

Manufacturing and Distribution

rely on third parties to formulate, manufacture and distribute gedatolisib.

We have entered into agreements with contract manufacturing

organizations (“CMOs”) to produce the drug substance gedatolisib and formulate, produce and package finished drug product

for clinical use and, if approved, commercial supply.

We have entered into agreements with distributors and a third-party logistics provider

(“3PL”) to distribute finished product for clinical use and, if approved, commercial supply.

We require all of our CMOs,

distributors, and our 3PL to conduct manufacturing and distribution activities in compliance with applicable laws, including current

good manufacturing practice (“cGMP”) and current good distribution practice, requirements.

We anticipate that these CMOs,

distributors, and 3PL will have the capacity to support both clinical- and commercial-scale production and distribution.

elect to enter into agreements with other CMOs to formulate and manufacture supplies of drug substance and finished drug product.

and Marketing

any of our product candidates are approved, we intend to market and commercialize them in the U.S.

and select international markets,

either alone or in partnership with others.

Cancer patients are primarily treated by medical, surgical, or radiation oncologists, and

we believe these physicians, and the multi-disciplinary teams surrounding them, including nurses, advanced practitioners, and pharmacists,

can be reached with a targeted sales force.

for Gedatolisib

pharmaceutical industry is characterized by rapid evolution of technologies and intense competition.

We face competition from major pharmaceutical

and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others.

Any product candidates that we successfully develop and commercialize will compete with approved treatment options, including off-label

therapies, and new therapies that may become available in the future.

Key considerations that would impact our ability to effectively

compete with other therapies include the efficacy, safety, method of administration, cost, level of promotional activity, and intellectual

property protection of our products.

Many of the companies against which we may compete have significantly greater financial resources

and expertise than we do in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory

approvals and marketing approved products.

are several PI3K, AKT, and mTOR inhibitors approved by the FDA, including PIQRAY and AFINITOR from Novartis AG, TRUQAP from AstraZeneca

plc, ITOVEBI from F.

Hoffmann-La Roche Ltd, COPIKTRA from Verastem, Inc., and ZYDELIG from Gilead Sciences, Inc.

We are aware that other

companies are, or may be, developing products for this indication, including BridgeBio Pharma Inc., Eli Lilly and Company, Kazia Therapeutics

Limited, Relay Therapeutics, Inc., Revolution Medicines Inc., and Takeda Pharmaceutical Company Limited.

There may be additional companies

with programs suitable for addressing these patient populations that could be competitive with our efforts but that have not yet disclosed

specific clinical development plans.

Smaller or early-stage companies, including oncology-focused therapeutics companies, may also prove

to be significant competitors, particularly through collaborative arrangements with large and established companies.

These companies

may also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites,

enrolling patients in clinical trials and acquiring technologies complementary to, or necessary for, our programs.

The availability of

reimbursement from government and private payors will also significantly impact the pricing and competitiveness of our products.

competitors may obtain FDA or other regulatory approvals for their products more rapidly than we may obtain approvals for our product

candidates, which could result in our competitors establishing a strong market position before we are able to commercialize our product

Market Opportunity

Based on our analysis of published epidemiological data, we estimate that approximately 37,000 patients in the U.S.

have HR+/HER2- ABC who have progressed after a CDK4/6 inhibitor.

If gedatolisib ultimately receives FDA approval for the treatment

of both PIK3CA WT and PIK3CA MT populations,

using internal duration of treatment estimates and pricing assumptions consistent with currently available novel therapeutics for breast

cancer, we estimate the total addressable market for gedatolisib in the second-line setting is more than $5.0 billion.

significant penetration our research is suggesting we can achieve, we believe it is reasonable to estimate that a second-line indication

for gedatolisib could potentially generate peak revenue of up to $2.5 billion annually.

success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, to operate without

infringing the proprietary rights of others, and to prevent others from infringing our proprietary rights.

We plan to protect our proprietary

positions using a variety of methods, which include protecting current U.S.

and foreign patents related to proprietary technology, inventions

and improvements and prosecuting additional U.S.

and foreign patents that we determine are important to the development and implementation

of our business.

For example, we, our licensors, or our collaborators currently have, or are pursuing, patents covering the composition

of matter for our drug product candidates and we plan to generally pursue patent protection covering methods-of-use for one or more clinical

We also rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing opportunities

to develop and maintain our proprietary position.

Gedatolisib Patents

We entered into the Gedatolisib License Agreement

with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under Pfizer patents and know-how to develop, manufacture

and commercialize gedatolisib.

We have exclusive licenses under the Gedatolisib License Agreement to patent rights in the U.S.

foreign jurisdictions relating to gedatolisib.

The patent rights in-licensed under the Gedatolisib License Agreement include 12 granted

patents in the U.S.

and more than 290 patents granted in foreign jurisdictions including Australia, Canada, China, France, Germany, Spain,

United Kingdom and Japan.

patent covering gedatolisib as a composition of matter has a statutory expiration date in December 2029

(including 209 days of Patent Term Adjustment) and a U.S.

patent that covers the cyclodextrin formulation of gedatolisib that is currently

in clinical development expires in January 2041 (including 578 days of Patent Term Adjustment), not including any patent term extension

that may be awarded by the FDA, and relevant foreign counterparts.

CELsignia Patents

With respect to CELsignia, we have six issued U.S.

patents and 30 issued international patents covering our diagnostic approach using cell signaling analysis in living patient cells to

guide treatment of patients with targeted therapies and cell sample preparation methods.

The earliest expiration date of the patents is

In addition, we have developed significant proprietary know-how and trade secrets for the various cell sample preparation and cellular

analysis methods we have developed.

Product Trademark

We have applied for trademark protection for our preferred

commercial product tradename.

While we expect the trademark to issue, the FDA ultimately will determine whether we can use the trademark

with our product.

Trade Secrets

In addition to patents, we rely on trade secrets and

know-how to develop and maintain our competitive position.

We typically rely on trade secrets to protect aspects of our business that

are not amenable to, or that we do not consider appropriate for, patent protection.

We protect trade secrets and know-how by establishing

confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and partners.

These agreements generally provide that all confidential information developed or made known during the course of an individual or entity’s

relationship with us must be kept confidential during and after the relationship.

These agreements also generally provide that all inventions

resulting from work performed for us or relating to our business and conceived or completed during the period of employment or assignment,

as applicable, shall be our exclusive property.

In addition, we take other appropriate precautions, such as physical and technological

security measures, to guard against misappropriation of our proprietary information by third parties.

Government Regulation

Approval of Gedatolisib and Other Drug Products

Government authorities in the U.S.

at the federal,

state and local level and in other countries and jurisdictions, including the EU, extensively regulate, among other things, the research,

development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,

post-approval monitoring and reporting, marketing and export and import of drug products, such as gedatolisib and other drugs that may

be used in combination with or compete with gedatolisib.

Generally, before a new drug can be marketed, considerable data demonstrating

its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority and submitted for review

and approved by the regulatory authority.

The regulatory approval process is time-consuming and requires significant capital expenditures.

We plan to protect our

proprietary positions using a variety of methods, which include obtaining U.S.

and foreign patents related to our inventions and

improvements, and prosecuting additional U.S.

and foreign patents that we determine are important to the development and

implementation of our business.

For example, we, directly and via our licensors, currently have, or are

pursuing, patents covering the composition of matter, formulation, and methods of using our drug product candidates and we plan to

pursue additional patent protection as appropriate.

We also rely on trade secrets, trademarks, know-how, continuing technological

innovation and potential in-licensing opportunities to develop and maintain our proprietary position.

entered into the Gedatolisib License Agreement with Pfizer in April 2021, pursuant to which we acquired exclusive worldwide rights under

Pfizer patents and know-how to develop, manufacture and commercialize gedatolisib.

We have an exclusive license under the Gedatolisib

License Agreement to patent rights in the U.S.

and numerous foreign jurisdictions relating to gedatolisib, in addition to our own patents.

The patent rights we own or which we have in-licensed under the Gedatolisib License Agreement include 13 granted patents in the U.S.

and more than 297 patents granted in numerous foreign jurisdictions.

patent covering gedatolisib as a composition of matter has

a statutory expiration date in December 2029 (including 209 days of Patent Term Adjustment), a U.S.

patent that covers the cyclodextrin

formulation of gedatolisib that is currently used in our clinical trials expires in January 2041 (including 578 days of Patent Term Adjustment),

patent that covers the method of using gedatolisib in breast cancer expires in August 2042 (including 37 days of Patent Term

Adjustment), not including any Patent Term Extension that may be awarded by the U.S.

Patent and Trademark Office (“USPTO”),

and relevant foreign counterparts.

Issued patents will, as appropriate, be listed in the FDA’s Approved Drug Products with Therapeutic

Equivalence Evaluations (“Orange Book”).

have applied for trademark protection for our preferred commercial product tradename, and the USPTO has allowed the tradename for

registration.

The FDA has conditionally approved the use of this tradename subject to the FDA’s approval of our NDA.

addition to patents, we rely on trade secrets and know-how to develop and maintain our competitive position.

We typically rely on trade

secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.

protect trade secrets and know-how by establishing confidentiality agreements and invention assignment agreements with our employees,

consultants, scientific advisors, contractors and partners.

These agreements generally provide that all confidential information developed

or made known during the course of an individual or entity’s relationship with us must be kept confidential during and after the

relationship.

These agreements also generally provide that all inventions resulting from work performed for us or relating to our business

and conceived or completed during the period of employment or assignment, as applicable, shall be our exclusive property.

we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our

proprietary information by third parties.

of Gedatolisib and Other Drug Products

authorities in the U.S.

at the federal, state and local level and in other countries and jurisdictions, including the EU, extensively

regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage,

record-keeping, promotion, advertising, marketing, distribution, post-approval monitoring and reporting, and export and import of drug

products, such as gedatolisib and other drugs that may be used in combination with, or compete with, gedatolisib.

Generally, before a

new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format

specific for each regulatory authority and submitted for review and approved by the regulatory authority.

The regulatory approval process

is time-consuming and requires significant capital expenditures.

Approval Process

Overview of FDA Approval Process

In the U.S., pharmaceutical products are subject to

extensive regulation by the FDA.

The Federal Food, Drug, and Cosmetic Act (the “FDC Act”), and other federal and state statutes

and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling,

promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

of FDA Approval Process

the U.S., pharmaceutical products are subject to extensive regulation by the FDA.

The Federal Food, Drug, and Cosmetic Act, and other

federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping,

approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of

pharmaceutical products.

Failure to comply with applicable U.S.

requirements may subject a company to a variety of administrative or judicial sanctions, such as

FDA refusal to approve pending New Drug Applications (“NDAs”), warning or untitled letters, product recalls, product seizures,

total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.

requirements may subject a company to a variety of administrative or

judicial sanctions, such as FDA refusal to approve pending NDAs, warning or untitled letters, product recalls, product seizures, total

or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.

The process required

by the FDA before a drug may be marketed in the United States generally involves the following:

● completion of nonclinical laboratory tests, animal studies and formulation studies according to good laboratory

practices (GLP), or other applicable regulations;

● submission to the FDA of an application for an investigational new drug application (“IND”),

which must become effective before human clinical trials may begin;

● performance of adequate and well-controlled human clinical trials according to the FDA’s regulations

commonly referred to as current good clinical practices (“GCPs”), to establish the safety and efficacy of the proposed drug

for its intended use;

● submission to the FDA of an NDA for a new drug;

● satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug

is produced to assess compliance with the FDA cGMPs, to assure that the facilities, methods and controls are adequate to preserve the

drug’s identity, strength, quality and purity;

● potential FDA inspection of the nonclinical and clinical trial sites that generated the data in support

● FDA review of the NDA.

by the FDA before a drug may be marketed in the U.S.

generally involves the following:

of nonclinical laboratory tests, animal studies and formulation studies according to good laboratory practices (“GLPs”),

or other applicable regulations;

to the FDA of an application for an investigational new drug application (“IND”), which must become effective before

human clinical trials may begin;

of adequate and well-controlled human clinical trials according to the FDA’s regulations commonly referred to as current good

clinical practices (“cGCPs”), to establish the safety and efficacy of the proposed drug for its intended use;

to the FDA of an NDA for a new drug;

completion of an FDA pre-approval inspection (“PAI”) of the manufacturing facility or facilities where the drug is produced

to assess compliance with the FDA cGMPs, to assure that the facilities, methods and controls are adequate to preserve the drug’s

identity, strength, quality and purity;

FDA Bioresearch Monitoring (“BIMO”) inspections

of the nonclinical and clinical trial sites that generated the data in support of the NDA;

acceptance, review and approval of the NDA.

lengthy process of seeking required approvals and the continuing need for compliance with applicable statutes and regulations require

the expenditure of substantial resources and approvals are inherently uncertain.

Preclinical and Clinical Stages

Preclinical tests include laboratory evaluation of

product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy

of the product.

The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory

The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information

about product chemistry, manufacturing and controls and a proposed clinical trial protocol.

Long term preclinical tests, such as animal

tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.

A 30-day waiting period after the submission

of each IND is required prior to the commencement of clinical testing in humans.

If the FDA has neither commented on nor questioned the

IND within this 30-day period, the clinical trial proposed in the IND may begin.

The clinical stage of development involves the administration

of the investigational product to healthy volunteers or disease-affected patients under the supervision of qualified investigators, generally

physicians not employed by, or under control of, the trial sponsor, in accordance with GCPs.

Clinical trials are conducted under protocols

detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the

parameters to be used to monitor subject safety and assess efficacy.

Each protocol, and any subsequent amendments to the protocol, must

be submitted to the FDA as part of an IND.

Furthermore, each clinical trial must be reviewed and approved by an Institutional Review Board

(“IRB”), for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating

in the clinical trials are minimized and are reasonable in relation to anticipated benefits.

The IRB also monitors the clinical trial

until completed.

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

● Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed

to a single dose and then multiple doses of the product candidate.

and Clinical Stages

tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics

and potential safety and efficacy of the product.

The conduct of the preclinical tests must comply with federal regulations and requirements,

including GLPs.

The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including

information about product chemistry, manufacturing and controls and a proposed clinical trial protocol.

Long term preclinical tests,

such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.

A 30-day waiting period after

the submission of an IND is required prior to the commencement of clinical testing in humans.

If the FDA has neither commented on nor

questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.

clinical stage of development involves the administration of the investigational product to healthy volunteers or disease-affected patients

under the supervision of qualified investigators, generally physicians not employed by, or under control of, the trial sponsor, in accordance

Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing

procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy.

protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of an IND.

Furthermore, each clinical trial

must be reviewed and approved by an Institutional Review Board (“IRB”), for each institution at which the clinical trial

will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation

to anticipated benefits.

The IRB also monitors the clinical trial until completed.

Human clinical trials are typically conducted in three

sequential phases, which may overlap or be combined:

1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to

a single dose and then multiple doses of the product candidate.

The primary purpose of these clinical trials is to assess the metabolism,

pharmacologic action, side effect tolerability and safety of the drug.

● Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits.

At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety

2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired benefits.

the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety

risks are identified, and a preliminary evaluation of efficacy is conducted.

● Phase 3 clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary

to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship

of the product and provide an adequate basis for product approval.

These trials may include comparisons with placebo and/or other comparator

3 clinical trials generally involve a larger number of patients at multiple sites and are designed to provide the data necessary

to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk

relationship of the product and provide an adequate basis for product approval.

These trials may include comparisons with placebo

and/or other comparator treatments.

The duration of treatment is often extended to mimic the actual use of a product during marketing.

A registrational trial is a clinical trial that adequately

meets regulatory agency requirements for the evaluation of a drug candidate’s efficacy and safety such that it can be used to justify

the approval of the drug.

Generally, registrational trials are Phase 3 trials but may be Phase 2 trials if the trial design provides a

reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.

Post-approval trials, sometimes referred to as Phase

4 clinical trials, may be conducted after initial marketing approval.

These trials are used to gain additional experience from the treatment

of patients in the intended therapeutic indication, particularly for long-term safety follow up.

Progress reports detailing the results of the clinical

trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur.

The FDA or the sponsor may

suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on various grounds, including a finding that

the research patients are being exposed to an unacceptable health risk.

Similarly, an IRB can suspend or terminate approval of a clinical

trial at its institution if the clinical trial is not being conducted in accordance with the requirements of the IRB or if the drug has

been associated with unexpected serious harm to patients.

There also are requirements governing the reporting

of ongoing clinical trials and completed clinical trial results to public registries.

Information about most clinical trials must be submitted

within specific timeframes for publication on the www.clinicaltrials.gov website.

Information related to the product, patient population,

phase of investigation, trial sites and investigators and other aspects of the clinical trial is made public as part of the registration

of the clinical trial.

Sponsors are also obligated to discuss the results of their clinical trials after completion.

Disclosure of the

results of these trials can be delayed in some cases for up to two years after the date of completion of the trial.

Competitors may use

this publicly available information to gain knowledge regarding the progress of development programs.

FDA Review and Approval Process

After completion of the required clinical testing,

an NDA is prepared and submitted to the FDA.

Prior to granting approval of the NDA, which is required before marketing of the product

may begin in the U.S., the FDA must determine whether to accept the submission and, thereafter, conduct an in-depth review.

may take a year or more.

The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating

to the product’s pharmacology, chemistry, manufacture and controls.

The cost of preparing and submitting an NDA is substantial.

The submission of an NDA to FDA, absent an applicable fee waiver, is subject to a substantial application user fee, currently $4,310,002

for Fiscal Year 2025, and the manufacturer and/or sponsor under an approved NDA are also subject to annual program fees for eligible products,

which are currently $403,889 for Fiscal Year 2025.

The FDA may also refer applications for novel drug

products, or drug products that present difficult questions of safety or efficacy, to an advisory committee—typically a panel that

includes clinicians and other experts—for review, evaluation and a recommendation as to whether the application should be approved.

The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.

Before approving an

NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP.

Additionally, the FDA will inspect the facility

or the facilities at which the drug is manufactured.

The FDA will not approve the product unless compliance with cGMP is satisfactory

and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.

After the FDA evaluates the NDA and the manufacturing

facilities, it issues either an approval letter or a complete response letter.

A complete response letter generally outlines the deficiencies

in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application.

If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an

approval letter.

The FDA has committed to reviewing such resubmissions in two to six months depending on the type of information included.

An approval letter authorizes commercial marketing

of the drug with specific prescribing information for specific indications.

As a condition of NDA approval, the FDA may require a risk

evaluation and mitigation strategy (“REMS”), to help ensure that the benefits of the drug outweigh the potential risks.

can include medication guides, communication plans for healthcare professionals and elements to assure safe use (“ETASU”).

ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain

circumstances, special monitoring and the use of patient registries.

The requirement for a REMS can materially affect the potential market

and profitability of the drug.

Moreover, product approval may require substantial post-approval testing and surveillance to monitor the

drug’s safety or efficacy.

Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained

or problems are identified following initial marketing.

Changes to some of the conditions established in an

approved application, including changes in indications, labeling or manufacturing processes or facilities, require submission and FDA

approval of a new NDA or NDA supplement before the change can be implemented.

An NDA supplement for a new indication typically requires

clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements

as it does in reviewing NDAs.

registrational trial is a clinical trial that adequately meets regulatory agency requirements for the evaluation of a drug candidate’s

efficacy and safety such that it can be used to justify the approval of the drug.

Generally, registrational trials are Phase 3 trials

but may be Phase 2 trials if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there

is an unmet medical need.

Post-approval

trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval.

These trials are used to

gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow

reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse

events occur.

The FDA or the sponsor may suspend or terminate a clinical trial at any time, or the FDA may impose other sanctions on

various grounds, including a finding that the research patients are being exposed to an unacceptable health risk.

Similarly, an IRB can

suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with

the requirements of the IRB or if the drug has been associated with unexpected serious harm to patients.

also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.

about most clinical trials must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website.

related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial

is made public as part of the registration of the clinical trial.

Sponsors are also obligated to discuss the results of their clinical

trials after completion.

Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of

completion of the trial.

Competitors may use this publicly available information to gain knowledge regarding the progress of development

Review and Approval Process

completion of the required clinical testing, an NDA is prepared and submitted to the FDA.

Prior to granting approval of the NDA, which

is required before marketing of the product may begin in the U.S., the FDA must determine whether to accept the submission and, thereafter,

conduct an in-depth review.

This process may take a year or more.

The NDA must include the results of all preclinical, clinical and other

testing and a compilation of data relating to the product’s pharmacology, chemistry, manufacture and controls.

The cost of preparing

and submitting an NDA is substantial.

The submission of an NDA to the FDA, absent an applicable application user fee waiver, is subject

to a substantial application user fee, currently $4,682,003 for Fiscal Year 2026, and the manufacturer and/or sponsor under an approved

NDA are also subject to annual program fees for eligible products, which are currently $442,213 for Fiscal Year 2026.

As a company with

fewer than 500 employees submitting its first NDA, we have qualified for the application fee waiver.

FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to

an advisory committee—typically a panel that includes clinicians and other experts—for review, evaluation and a recommendation

as to whether the application should be approved.

The FDA is not bound by the recommendation of an advisory committee, but it generally

follows such recommendations.

Before approving an NDA, the FDA will typically conduct a BIMO inspection, including inspecting one or

more clinical sites to assure compliance with cGCPs.

Additionally, the FDA will conduct a PAI of the facility or the facilities at which

the finished drug is manufactured to assure compliance with cGMP.

The FDA will not approve the product unless compliance with cGMP is

satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.

the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter (“CRL”).

A CRL generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order

for the FDA to reconsider the application.

If, or when, those deficiencies have been addressed to the FDA’s satisfaction in a resubmission

of the NDA, the FDA will issue an approval letter.

The FDA has committed to reviewing such resubmissions in two to six months depending

on the type of information included.

approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.

As a condition

of NDA approval, the FDA may require a risk evaluation and mitigation strategy (“REMS”), to help ensure that the benefits

of the drug outweigh the potential risks.

REMS can include medication guides, communication plans for healthcare professionals, and elements

to assure safe use (“ETASU”).

ETASU can include, but are not limited to, special training or certification for prescribing

or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries.

The requirement for

a REMS can materially affect the potential market and profitability of the drug.

Moreover, product approval may require substantial post-approval

testing and surveillance to monitor the drug’s safety or efficacy.

Once granted, product approvals may be withdrawn if compliance

with regulatory standards is not maintained or problems are identified following initial marketing.

to some of the conditions established in an approved application, including changes in indications, labeling or manufacturing processes

or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented.

An NDA supplement

for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures

and actions in reviewing NDA supplements as it does in reviewing NDAs.

Marketing Exclusivity

Upon NDA approval of a new chemical entity (“NCE”),

which is a drug (i.e., gedatolisib) that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives

five years of marketing exclusivity during which the FDA cannot accept any Abbreviated New Drug Application (“ANDA”), seeking

approval of a generic version of that drug.

Certain changes to a drug, such as the addition of a new indication to the package insert,

are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the

An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed.

If there is no listed

patent in the Orange Book, there is no Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity

Patent Term Extension

After NDA approval, owners of relevant drug patents

may apply for up to a five-year patent extension for one patent.

The allowable patent term extension is calculated as half of the drug’s

testing phase—the time between IND and NDA submission—and all of the review phase—the time between NDA submission and

approval up to a maximum of five years.

The time can be shortened if the FDA determines that the applicant did not pursue approval with

due diligence.

The total patent term after the extension may not exceed 14 years from approval.

For patents that might expire during the application

phase, the patent owner may request an interim patent extension.

An interim patent extension increases the patent term by one year and

may be renewed up to four times.

For each interim patent extension granted, the post-approval patent extension is reduced by one year.

The director of the U.S.

Patent and Trademark Office must determine that approval of the drug covered by the patent for which a patent

extension is being sought is likely.

Interim patent extensions are not available for a drug for which an NDA has not been submitted.

Fast Track Designation

The FDA is required to facilitate the development,

and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which

there is no effective treatment, and which demonstrate the potential to address unmet medical needs for the condition.

Under the Fast

Track program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for a specific indication as

a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate.

The FDA must determine if the drug candidate

qualifies for Fast Track Designation within 60 days of receipt of the sponsor’s request.

Under the Fast Track program and the FDA’s accelerated

approval regulations, the FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit

to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical

endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible

morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability

or lack of alternative treatments.

In clinical trials, a surrogate endpoint is a measurement

of laboratory or clinical signs of a disease or condition that substitutes for a direct measurement of how a patient feels, functions

Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints.

A drug candidate approved

on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical

trials to confirm the effect on the clinical endpoint.

Failure to conduct required post-approval studies, or confirm a clinical benefit

during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis.

All promotional materials

for product candidates approved under accelerated regulations are subject to prior review by the FDA.

In addition to other benefits such as the ability

to use surrogate endpoints and engage in more frequent interactions with the FDA, the FDA may initiate review of sections of a Fast Track

drug’s NDA before the application is complete.

This rolling review is available if the applicant provides, and the FDA approves,

a schedule for the submission of the remaining information and the applicant pays applicable user fees.

However, the FDA’s time

period goal for reviewing an application does not begin until the last section of the NDA is submitted.

Additionally, the Fast Track Designation

may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

Breakthrough Therapy Designation

Breakthrough Therapy Designation by the FDA provides

more extensive development consultation opportunities with FDA senior staff, allows for the rolling review of the drug’s application

for approval and indicates that the product could be eligible for priority review if supported by clinical data at the time of application

submission for drugs that are intended to treat a serious or life-threatening disease or condition where preliminary clinical evidence

indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

Under the breakthrough therapy program, the sponsor of a new drug candidate may request that the FDA designate the drug candidate for

a specific indication as a breakthrough therapy concurrent with, or after, the filing of the IND for the drug candidate.

determine if the drug candidate qualifies for Breakthrough Therapy Designation within 60 days of receipt of the sponsor’s request.

Disclosure of Clinical Trial Information

Sponsors of clinical trials of FDA regulated products,

including drugs, are required to register and disclose certain clinical trial information.

Information related to the product, patient

population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as part

of the registration.

Sponsors are also obligated to discuss the results of their clinical trials after completion.

Disclosure of the results

of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial.

Competitors may

use this publicly available information to gain knowledge regarding the progress of development programs.

European Union Approval Process

In the EU, our product candidates may also be subject

to extensive regulatory requirements.

As in the U.S., medicinal products can be marketed only if a marketing authorization from the competent

regulatory agencies has been obtained.

Similar to the U.S., the various phases of preclinical and clinical research in the EU are subject

to significant regulatory controls.

The Clinical Trials Regulation

(EU) No 536/2014 came into effect in 2022.

The Clinical Trials Regulation is directly applicable in all the EU Member States, and repealed

the Clinical Trials Directive 2001/20/EC.

The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials

NDA approval of a new chemical entity (“NCE”), which is a drug (i.e., gedatolisib) that contains no active moiety that has

been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot accept

any Abbreviated New Drug Application (“ANDA”), seeking approval of a generic version of that drug.

Certain changes to a drug,

such as the addition of a new indication to the package insert, are associated with a three-year period of exclusivity during which the

FDA cannot approve an ANDA for a generic drug that includes the change.

An ANDA may be submitted one year before NCE exclusivity expires

if a Paragraph IV certification is filed with the ANDA.

If there is no listed patent in the Orange Book, no ANDA may be filed before

the expiration of the exclusivity period.

If approved, we expect to receive five-year NCE exclusivity for gedatolisib.

Term Extension

NDA approval, owners of relevant drug patents may apply to the USPTO for up to a five-year patent term extension (“PTE”)

for one patent.

The allowable PTE is calculated as half of the drug’s testing phase—the time between IND and NDA submission—and

all of the review phase—the time between NDA submission and approval, up to a maximum of five years.

The time can be shortened

if the USPTO, in coordination with the FDA, determines that the applicant did not pursue approval with due diligence.

The total patent

term after the extension may not exceed 14 years from NDA approval.

We intend to seek five-year PTE should the FDA approve our NDA for

patents that might expire during the application phase, the patent owner may request an interim patent extension.

An interim patent extension

increases the patent term by one year and may be renewed up to four times.

For each interim patent extension granted, the post-approval

patent extension is reduced by one year.

The director of the USPTO must determine that approval of the drug covered by the patent for

which a patent extension is being sought is likely.

Interim patent extensions are not available for a drug for which an NDA has not been

Track Designation

FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or

life-threatening disease or condition for which there is no effective treatment, and which demonstrate the potential to address unmet

medical needs for the condition.

Under the Fast Track program, the sponsor of a new drug candidate may request that the FDA designate

the drug candidate for a specific indication as a Fast Track drug concurrent with, or after, the filing of the IND for the drug candidate.

The FDA must determine if the drug candidate qualifies for Fast Track designation within 60 days of receipt of the sponsor’s request.

Gedatolisib has received Fast Track designation from the FDA.

the Fast Track program and the FDA’s accelerated approval regulations, the FDA may approve a drug for a serious or life-threatening

illness that provides meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably

likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality,

that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account

the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.

clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutes for

a direct measurement of how a patient feels, functions or survives.

Surrogate endpoints can often be measured more easily or more rapidly

than clinical endpoints.

A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including

the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint.

Failure to conduct required

post-approval studies, or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the

market on an expedited basis.

All promotional materials for product candidates approved under accelerated regulations are subject to

prior review by the FDA.

addition to other benefits such as the ability to use surrogate endpoints and engage in more frequent interactions with the FDA, the

FDA may initiate review of sections of a Fast Track drug’s NDA before the application is complete.

This rolling review is available

if the applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant pays applicable

user fees if not waived.

However, the FDA’s time period goal for reviewing an application does not begin until the last section

of the NDA is submitted.

Additionally, the Fast Track designation may be withdrawn by the FDA if the FDA believes that the designation

is no longer supported by data emerging in the clinical trial process.

Therapy Designation

Therapy designation by the FDA provides more extensive development consultation opportunities with FDA senior staff, allows for the rolling

review of the drug’s application for approval and indicates that the product could be eligible for Priority Review if supported

by clinical data at the time of application submission for drugs that are intended to treat a serious or life-threatening disease or

condition where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies

on one or more clinically significant endpoints.

Under the Breakthrough Therapy program, the sponsor of a new drug candidate may request

that the FDA designate the drug candidate for a specific indication as a Breakthrough Therapy concurrent with, or after, the filing of

the IND for the drug candidate.

The FDA must determine if the drug candidate qualifies for Breakthrough Therapy designation within 60

days of receipt of the sponsor’s request.

Gedatolisib received Breakthrough Therapy

Oncology Review (“RTOR”)

is an FDA review program within the Oncology Center of Excellence that allows sponsors to submit key sections of an oncology NDA on a

rolling basis.

The intent of RTOR is to start FDA review earlier, improve efficiency, and potentially shorten overall NDA review times.

On August 27, 2025, the FDA granted our request to submit our NDA on a rolling basis via the RTOR program.

Priority Review is a designation by the FDA that shortens the review timeline for certain marketing applications, including NDAs.

Review reduces the FDA’s PDUFA goal review time from the standard 10 months to six months.

The FDA grants Priority Review if the

NDA is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness

over available therapies.

On January 16, 2026, the FDA accepted our NDA and awarded Priority Review, with a PDUFA goal date

of July 17, 2026.

of Clinical Trial Information

of clinical trials of FDA regulated products, including drugs, are required to register and disclose certain clinical trial information.

Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the

clinical trial is then made public as part of the registration at www.clinicaltrials.gov.

Sponsors are also obligated to discuss the results

of their clinical trials after completion.

Disclosure of the results of these trials can be delayed in certain circumstances for up to

two years after the date of completion of the trial.

Competitors may use this publicly available information to gain knowledge regarding

the progress of development programs.

Union Approval Process

the EU, our product candidates may also be subject to extensive regulatory requirements.

As in the U.S., medicinal products can be marketed

only if a marketing authorization from the competent regulatory agencies has been obtained.

Similar to the U.S., the various phases of

preclinical and clinical research in the EU are subject to significant regulatory controls.

Clinical Trials Regulation (EU) No 536/2014 came into effect in 2022.

The Clinical Trials Regulation is directly applicable in all the

EU Member States, and repealed the Clinical Trials Directive 2001/20/EC.

The Clinical Trials Regulation aims to simplify and streamline

the approval of clinical trials in the EU.

The main characteristics of the regulation include:

a streamlined application procedure via a single-entry point, the Clinical

Trial Information System (“CTIS”);

a streamlined application procedure via

a single-entry point, the Clinical Trial Information System;

a single set of documents to be prepared and submitted for the application

10 unchanged sentences

However, overall related timelines will be defined by the Clinical Trials Regulation.

To obtain a marketing authorization of a drug in the

EU, we may submit Marketing Authorisation Applications (“MAA”), either under the so-called centralized or national authorization

Centralized Procedure

The centralized procedure provides for the grant of

a single marketing authorization following a favorable opinion by the European Medicines Agency (“EMA”), that is valid in

all EU Member States, as well as Iceland, Liechtenstein and Norway.

The centralized procedure is compulsory for medicines produced by

specified biotechnological processes, products designated as orphan medicinal products, advanced therapy medicines (such as gene-therapy,

somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of specified

diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral

The centralized procedure is optional for products that represent a significant therapeutic, scientific or technical innovation,

or whose authorization would be in the interest of public health.

Under the centralized procedure, the maximum timeframe for the evaluation

of an MAA by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant

in response to questions asked by the Committee of Medicinal Products for Human Use (the “CHMP”).

Accelerated assessment might

be granted by the CHMP in exceptional cases when a medicinal product is expected to be of a major public health interest, particularly

from the point of view of therapeutic innovation.

The timeframe for the evaluation of an MAA under the accelerated assessment procedure

is 150 days, excluding stop-clocks.

National Authorization Procedures

There are also two other possible routes to authorize

medicinal products in several EU countries, which are available for investigational medicinal products that fall outside the scope of

the centralized procedure:

● Decentralized procedure.

Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one

EU country of medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of

the centralized procedure.

● Mutual recognition procedure.

obtain a marketing authorization of a drug in the EU, we may submit Marketing Authorisation Applications (“MAA”), either

under the so-called centralized or national authorization procedures.

centralized procedure provides for the grant of a single marketing authorization following a favorable opinion by the European Medicines

Agency (the “EMA”), that is valid in all EU Member States, as well as Iceland, Liechtenstein and Norway.

The centralized

procedure is compulsory for medicines produced by specified biotechnological processes, products designated as orphan medicinal products,

advanced therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active

substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes, neurodegenerative disorders or autoimmune

diseases and other immune dysfunctions and viral diseases.

The centralized procedure is optional for products that represent a significant

therapeutic, scientific or technical innovation, or whose authorization would be in the interest of public health.

Under the centralized

procedure, the maximum timeframe for the evaluation of an MAA by the EMA is 210 days, excluding clock stops, when additional written

or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human

Use (the “CHMP”).

Accelerated assessment might be granted by the CHMP in exceptional cases when a medicinal product is expected

to be of a major public health interest, particularly from the point of view of therapeutic innovation.

The timeframe for the evaluation

of an MAA under the accelerated assessment procedure is 150 days, excluding clock stops.

Authorization Procedures

are also two other possible routes to authorize medicinal products in several EU countries, which are available for investigational medicinal

products that fall outside the scope of the centralized procedure:

Decentralized

Using the decentralized procedure, an applicant may apply for simultaneous authorization in more than one EU country of

medicinal products that have not yet been authorized in any EU country and that do not fall within the mandatory scope of the centralized

recognition procedure.

In the mutual recognition procedure, a medicine is first authorized in one EU Member State, in accordance

with the national procedures of that country.

Following this, further marketing authorizations can be sought from other EU countries in

a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.

Under the above-described procedures, before granting

an MAA, the EMA or the competent authorities of the Member States of the European Economic Area (“EEA”), assess the risk-benefit

balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.

EU Regulatory Exclusivity

In the EU, new products authorized for marketing (i.e.,

reference products) qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization.

The data exclusivity period prevents generic applicants from relying on the preclinical and clinical trial data contained in the dossier

of the reference product when applying for a generic marketing authorization in the EU during a period of eight years from the date on

which the reference product was first authorized in the EU.

The market exclusivity period prevents a successful generic applicant from

commercializing its product in the EU until ten years have elapsed from the initial authorization of the reference product in the EU.

The ten-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years,

the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation

prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

Drug Approval-Related Regulations – Rest of the World

For other countries outside of the EU and the U.S.,

such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing,

pricing and reimbursement vary from jurisdiction to jurisdiction.

Additionally, the clinical trials must be conducted in accordance with

cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal

of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.

Regulations of CELsignia Tests

CLIA and CMS for Diagnostic

Our CELsignia tests are laboratory developed tests

(“LDTs”), and subject to regulation under the Clinical Laboratory Improvement Amendments (“CLIA”).

for Medicare & Medicaid Services (“CMS”), an agency within the U.S.

Department of Health and Human Services (“HHS”),

regulates all clinical laboratory testing (except research) performed on humans in the United States through CLIA.

All clinical laboratories

that perform clinical lab services on human specimens for the purpose of providing information on the diagnosis, prevention or treatment

of disease must receive CLIA certification.

We received our CLIA certification in 2016.

We also had our laboratory certified by the College

of American Pathologists (“CAP”), in 2016, an organization recognized by CMS as a third-party reviewer of clinical laboratories.

Several states, including, among others, New York and California, require licensure of out-of-state labs that receive specimens from the

state and compliance with the state’s individual laboratory regulations.

FDA for Diagnostics

FDA approval or clearance is not currently required

for CELsignia tests offered as a stand-alone LDT test.

If we are partnered with a drug company to launch a CELsignia test as a companion

diagnostic for a new drug indication, we would be required to obtain premarket approval (PMA), in conjunction with the pharmaceutical

company seeking a new drug approval for the matching therapy.

Historically, the FDA has exercised enforcement discretion with respect

to tests performed solely in a central laboratory, like the CELsignia tests or LDTs.

The FDA has not required laboratories that furnish

only LDTs to comply with the agency’s requirements for medical devices (e.g., establishment registration, device listing, quality

systems regulations, premarket clearance or premarket approval, and post-market controls).

However, the FDA has discussed potential regulation

of LDTs and may regulate LDTs in the future.

Pricing and Reimbursement of our Product Candidates

Significant uncertainty exists as to the coverage

and reimbursement status of any products we sell or may sell.

Sales of our drug products will depend, in part, on the extent to which

the costs of the products will be covered by third-party payors, including government health programs such as VA, Tricare, Medicare and

Medicaid, commercial health insurers, and other managed care organizations.

In order to obtain coverage and reimbursement for

our drug product, we will conduct extensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness

of our product.

Whether or not we conduct such studies, our products may not be considered medically necessary or cost-effective.

A third-party

payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.

one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate

reimbursement, for the product.

Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize

an appropriate return on our investment in product development.

The containment of healthcare costs has become a priority

of federal, state and foreign governments, and the prices of drugs have been a focus in this effort.

Third-party payors are increasingly

challenging the prices charged for medical products, examining the medical necessity and reviewing the cost-effectiveness of drug products

and questioning product safety and efficacy.

If these third-party payors do not consider our product to be cost-effective compared to

other available products, they may not cover our product or, if they do, the level of reimbursement may not be sufficient to allow us

to realize a profit on the use of our product.

government, state legislatures and foreign governments have shown significant

interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls and

restrictions on reimbursement.

Adoption of such controls and measures, and tightening of restrictive policies in jurisdictions with existing

controls and measures, could limit payments for our product and could adversely affect our net revenue and results.

In August 2022, the Inflation Reduction Act (“IRA”)

was signed into law, which, among other things, requires manufacturers of certain drugs to engage in price negotiations with Medicare

(beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation, and

replaces the Part D coverage gap discount program with a new discounting program.

We will evaluate the impact of the IRA on our business,

operations and financial condition and results as the full effect of the IRA on our business strategy and the pharmaceutical industry

remains uncertain.

In addition, changes to the Medicaid program or the federal 340B drug pricing program, which imposes ceilings on prices

that drug manufacturers can charge for medications sold to certain health care facilities, could have a material impact on our business

following commercialization.

We expect to see continued focus by Congress and the Trump Administration on regulating pricing, which could

result in legislative and regulatory changes designed to control costs.

Pricing and reimbursement schemes vary widely from

country to country.

Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular

drug product to currently available drugs.

The downward pressure on healthcare costs in general, particularly prescription drugs, has

become intense.

As a result, increasingly high barriers are being erected to the entry of new drug products.

In addition, in some countries,

cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country.

Any country that has

price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for our product.

Coverage policies, third-party reimbursement rates

and pricing regulation may change at any time.

Other Healthcare Laws

Manufacturing, sales, promotion and other activities

following product approval are also subject to regulation by numerous regulatory authorities in the U.S.

in addition to the FDA, including

CMS, the HHS Office of Inspector General and HHS Office for Civil Rights, other divisions of the HHS, the Department of Justice and state

regulatory bodies including Boards of Pharmacy and Price Transparency Boards.

Healthcare systems, physicians, pharmacists, and third-party

payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval.

and future arrangements with third-party payors, healthcare systems, physicians and pharmacists may expose us to broadly applicable fraud

and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through

which we market, sell and distribute our drug product.

In the U.S., these laws include, without limitation, state and federal anti-kickback,

false claims, physician payment transparency, and patient data privacy and security laws and regulations, including but not limited to

those described below.

federal Anti-Kickback Statute (“AKS”)

prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting, receiving or providing

any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or arranging for

or recommending the purchase, lease or order of any good, facility, item or service reimbursable, in whole or in part, under Medicare,

Medicaid or other federal healthcare programs.

The term “remuneration” has been broadly interpreted to include anything of

The AKS has been interpreted to apply to arrangements between pharmaceutical and medical device manufacturers on the one hand and

prescribers, purchasers, formulary managers and beneficiaries on the other hand.

A person does not need to have actual knowledge of the

statute or specific intent to violate it in order to have committed a violation of the AKS.

Moreover, a claim including items or services resulting

from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, which imposes

civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for,

among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for

items or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary

items or services.

This could apply even if we are not submitting claims directly to payors as would be the case with drug products.

In addition, under a federal law directed at “self-referral,”

commonly known as the “Stark Law,” there are prohibitions, with certain exceptions, on referrals for certain designated health

services, including laboratory services, that are covered by the Medicare and Medicaid programs by physicians who personally, or through

a family member, have an investment or ownership interest in, or a compensation arrangement with, an entity performing the tests.

prohibition also extends to payment for any testing referred in violation of the Stark Law.

Bills submitted in violation of the Stark

Law may not be paid by Medicare or Medicaid, and there may be significant penalties for violations.

Many states have comparable laws that

are not limited to Medicare and Medicaid referrals.

These regulations present compliance and litigation

risks for our business and others in our industry.

We incur compliance-related expenses and expect to incur additional expenses if and

when our products are commercialized.

We may be subject to penalties or limitations on government program participation if we are found

to have violated these regulations.

The federal Health Insurance Portability and Accountability

Act of 1996 (“HIPAA”) created additional federal criminal statutes that prohibit, among other actions, knowingly and willfully

executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises,

any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors,

knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a

healthcare offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious

or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.

Similar to the AKS,

a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a

In addition, there has been a recent trend of increased

federal and state regulation of payments made to physicians and certain other healthcare providers, and their ownership and investment

The Affordable Care Act (the “ACA”), imposed, among other things, annual reporting requirements through the Physician

Payments Sunshine Act for covered manufacturers for certain payments and “transfers of value” to these providers.

to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment

interests may result in civil monetary penalties.

We may also be subject to data privacy and security

regulation by both the federal government and the states in which we conduct our business.

HIPAA, as amended by the Health Information

Technology for Economic and Clinical Health Act (“HITECH”), and their respective implementing regulations, impose specified

requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities

and their business associates.

Among other things, HITECH made HIPAA’s security standards directly applicable to “business

associates,” defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected

health information in connection with providing a service for or on behalf of a covered entity, although it is unclear that we would be

considered a “business associate” in the normal course of our business.

HITECH also increased the civil and criminal penalties

that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority

to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney’s fees and

costs associated with pursuing federal civil actions.

In addition, state laws govern the privacy and security of health information in

certain circumstances, many of which differ from each other in significant ways and may not have the same requirements, thus complicating

compliance efforts.

See “European Data Collection” below for a discussion of data privacy and security enactments of the EU.

At the state level, the California Consumer Privacy

Act (the “CCPA”), as amended and expanded by the California Privacy Rights Act (the “CPRA”), impose data protection

obligations on certain businesses.

While we believe that certain limited exceptions under the CPRA for clinical trial data and other health

data would apply to us, these regulations exemplify the vulnerability of our business to the evolving regulatory environment related to

personal data and protected health information, which causes us to incur compliance costs.

Privacy legislation similar to the CCPA has

been adopted in other U.S.

states, including Colorado, Connecticut, Kentucky, Maryland, Minnesota, Montana, New Jersey, New Hampshire,

Nevada, Oregon, Rhode Island, Tennessee, Texas, Utah, and Virginia.

States and foreign jurisdictions also have fraud and

abuse laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and

claims involving healthcare items or services.

Some state laws also require pharmaceutical companies to comply with the pharmaceutical

industry’s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers

to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures

or drug pricing.

In order to sell products, we will need to comply

with state laws, including those that require the registration of manufacturers and wholesale distributors of drug and biological products.

Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs,

file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities,

and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician

prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and

marketing practices.

If and when we commercialize our products, all of our activities are potentially subject to federal and state consumer

protection and unfair competition laws.

The scope and enforcement of each of these laws is

uncertain and subject to rapid change in the current environment, especially in light of the lack of applicable precedent and regulations.

If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may

be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational

harm, diminished profits and future earnings, imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare

and Medicaid, and the curtailment or restructuring of our business strategy operations, as well as additional reporting obligations and

oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these

laws, any of which could adversely affect our ability to operate our business and our financial results.

If any of the physicians or other

healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be

subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities,

can be time- and resource consuming and can divert a company’s attention from the business.

European Data Collection

We are subject to the General Data Protection Regulation

(the “GDPR”), and associated Data Protection Legislation, which govern the collection and use of personal data as it pertains

to the EU/EEA/UK.

Following this, further marketing authorizations can be sought from other EU countries

in a procedure whereby the countries concerned agree to recognize the validity of the original, national marketing authorization.

the above-described procedures, before granting an MAA, the EMA or the competent authorities of the Member States of the European Economic

Area (the “EEA”), assess the risk-benefit balance of the product on the basis of scientific criteria concerning its quality,

safety and efficacy.

Regulatory Exclusivity

the EU, new products authorized for marketing (i.e., reference products) qualify for eight years of data exclusivity and an additional

two years of market exclusivity upon marketing authorization.

The data exclusivity period prevents generic applicants from relying on

the preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic marketing authorization

in the EU during a period of eight years from the date on which the reference product was first authorized in the EU.

The market exclusivity

period prevents a successful generic applicant from commercializing its product in the EU until ten years have elapsed from the initial

authorization of the reference product in the EU.

The ten-year market exclusivity period can be extended to a maximum of eleven years

if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new

therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical

benefit in comparison with existing therapies.

Approval-Related Regulations – Rest of the World

other countries outside of the EU and the U.S., such as countries in Eastern Europe, Latin America or Asia, the requirements governing

the conduct of clinical trials, product licensing, pricing and reimbursement vary from jurisdiction to jurisdiction.

Additionally, the

clinical trials must be conducted in accordance with cGCP requirements and the applicable regulatory requirements and the ethical principles

that have their origin in the Declaration of Helsinki.

If we fail to comply with applicable foreign regulatory requirements, we may be

subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating

restrictions and criminal prosecution.

and Reimbursement of our Product Candidates

uncertainty exists as to the coverage and reimbursement status of any products we sell or may sell.

Sales of our drug products will depend,

in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs

such as VA, Tricare, Medicare and Medicaid, commercial health insurers, and other managed care organizations.

order to obtain coverage and reimbursement for our drug product, we will conduct extensive pharmacoeconomic studies in order to demonstrate

the medical necessity and cost-effectiveness of our product.

Whether or not we conduct such studies, our products may not be considered

medically necessary or cost-effective.

A third-party payor’s decision to provide coverage for a product does not imply that an

adequate reimbursement rate will be approved.

Further, one payor’s determination to provide coverage for a product does not assure

that other payors will also provide coverage, and adequate reimbursement, for the product.

Third-party reimbursement may not be sufficient

to enable us to maintain price levels high enough to realize an appropriate return on our investment in product development.

containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a

focus in this effort.

Third-party payors are increasingly challenging the prices charged for medical products, examining the medical

necessity and reviewing the cost-effectiveness of drug products and questioning product safety and efficacy.

If these third-party payors

do not consider our product to be cost-effective compared to other available products, they may not cover our product or, if they do,

the level of reimbursement may not be sufficient to allow us to realize a profit on the use of our product.

government, state

legislatures and foreign governments have shown significant interest in implementing cost-containment programs to limit the growth of

government-paid healthcare costs, including price controls and restrictions on reimbursement.

Adoption of such controls and measures,

and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for our product and

could adversely affect our net revenue and results.

August 2022, the Inflation Reduction Act (the “IRA”) was signed into law, which, among other things, requires manufacturers

of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare

Part D to penalize price increases that outpace inflation, and replaces the Part D coverage gap discount program with a new discounting

Gedatolisib, if approved, will be subject to these provisions of the IRA, and we have taken these provisions into account when developing our business strategy, operations, and our projected financial condition and results.

In addition, changes to the Medicaid

program or the federal 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications

sold to certain health care facilities, could have a material impact on our business following commercialization.

We expect to see continued

focus by Congress and the Trump Administration on regulating drug pricing, which could result in legislative and regulatory changes designed

to control costs.

and reimbursement schemes vary widely from country to country.

Some countries may require the completion of additional studies that compare

the cost-effectiveness of a particular drug product to currently available drugs.

The downward pressure on healthcare costs in general,

particularly prescription drugs, has become intense.

As a result, increasingly high barriers are being erected to the entry of new drug

In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing

within a country.

Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement

and pricing arrangements for our product.

policies, third-party reimbursement rates and pricing regulation may change at any time.

Healthcare Laws

Manufacturing,

sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in

in addition to the FDA, including CMS, the HHS Office of Inspector General and HHS Office for Civil Rights, other divisions

of the HHS, the Department of Justice, and state regulatory bodies including Boards of Pharmacy and Price Transparency Boards.

systems, physicians, pharmacists, and third-party payors will play a primary role in the recommendation and prescription of any products

for which we obtain marketing approval.

Our current and future arrangements with third-party payors, healthcare systems, physicians and

pharmacists may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business

or financial arrangements and relationships through which we market, sell and distribute our drug product.

In the U.S., these laws include,

without limitation, state and federal anti-kickback, false claims, physician payment transparency, and patient data privacy and security

laws and regulations, including but not limited to those described below.

federal Anti-Kickback Statute (the “AKS”) prohibits, among other things, any person or entity from knowingly and willfully

offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return

for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any good, facility, item or service

reimbursable, in whole or in part, under Medicare, Medicaid or other federal healthcare programs.

The term “remuneration”

has been broadly interpreted to include anything of value.

The AKS has been interpreted to apply to arrangements between pharmaceutical

and medical device manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other hand.

A person does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation

a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the

federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals

or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including

Medicare and Medicaid) claims for items or services that are false or fraudulent, claims for items or services not provided as claimed,

or claims for medically unnecessary items or services.

This could apply even if we are not submitting claims directly to payors as would

be the case with sales of drug products.

addition, under a federal law directed at “self-referral,” commonly known as the “Stark Law,” there are prohibitions,

with certain exceptions, on referrals for certain designated health services, including laboratory services, that are covered by the

Medicare and Medicaid programs by physicians who personally, or through a family member, have an investment or ownership interest in,

or a compensation arrangement with, an entity performing the tests.

The prohibition also extends to payment for any testing referred

in violation of the Stark Law.

Bills submitted in violation of the Stark Law may not be paid by Medicare or Medicaid, and there may be

significant penalties for violations.

Many states have comparable laws that are not limited to Medicare and Medicaid referrals.

regulations present compliance and litigation risks for our business and others in our industry.

We incur compliance-related expenses

and expect to incur additional expenses if and when our products are commercialized.

We may be subject to penalties or limitations on

government program participation if we are found to have violated these regulations.

federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) created additional federal criminal statutes

that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by

means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody

of, any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare

benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing

or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of

or payment for healthcare benefits, items or services.

Similar to the AKS, a person or entity does not need to have actual knowledge

of the statute or specific intent to violate it in order to have committed a violation.

addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and certain other healthcare

providers, and their ownership and investment interests.

The Affordable Care Act, imposed, among other things, annual reporting requirements

through the Physician Payments Sunshine Act for covered manufacturers for certain payments and “transfers of value” to these

Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership

or investment interests may result in civil monetary penalties.

may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and

their respective implementing regulations, impose specified requirements relating to the privacy, security and transmission of

individually identifiable health information held by covered entities and their business associates.

Among other things, HITECH made

HIPAA’s security standards directly applicable to “business associates,” defined as independent contractors or

agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a

service for or on behalf of a covered entity.

Although we are not a “covered entity” and we would not be considered a

“business associate” in the normal course of our business and therefore not regulated by HIPAA, our business frequently interacts with covered entities and business associates

who are subject to HIPAA.

In addition, state laws govern the privacy and security of

health information in certain circumstances, many of which differ from each other in significant ways and may not have the same

requirements, thus complicating compliance efforts.

See “International Data Collection” below for a discussion of data

privacy and security enactments of the EU.

the state level, the California Consumer Privacy Act, as amended and expanded by the California Privacy Rights Act (collectively,

the “CCPA”), imposes data protection obligations on certain businesses.

Although we are not currently regulated by any comprehensive state privacy law, we expect we will be regulated by

such laws in the future as our business develops.

While there are certain limited exceptions under

the CCPA for clinical trial data and other health data that would apply to us, these regulations exemplify the vulnerability of our

business to the evolving regulatory environment related to personal data and protected health information, which causes us to incur

compliance costs.

Privacy legislation similar to the CCPA has been adopted in many other U.S.

states, and regulation of the collection, use, and disclosure of personal information remains a common focus of state legislation.

and foreign jurisdictions also have fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may

apply to sales or marketing arrangements and claims involving healthcare items or services.

Some state laws also require pharmaceutical

companies to comply with the brand pharmaceutical industry’s voluntary compliance guidelines (i.e., the PhRMA Code) and the

relevant federal government compliance guidances, and require drug manufacturers to report information related to payments and other

transfers of value to physicians and other healthcare providers, marketing expenditures, or drug pricing.

order to sell products, we will need to comply with state laws, including those that require the registration of manufacturers and wholesale

distributors of drug and biological products.

Several states have enacted legislation requiring pharmaceutical and biotechnology companies

to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,

pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other

healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales

and marketing, and to prohibit certain other sales and marketing practices.

If and when we commercialize our products, all of our activities

are potentially subject to federal and state consumer protection and unfair competition laws.

scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment, especially in light

of the lack of applicable precedent and regulations.

If our operations are found to be in violation of any of these laws or any other

governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,

fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, exclusion of drugs

from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our business strategy

operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other

agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business

and our financial results.

If any of the physicians or other healthcare providers or entities with whom we expect to do business is found

to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including

exclusions from government funded healthcare programs.

Ensuring business arrangements comply with applicable healthcare laws, as well

as responding to possible investigations by government authorities, can be time- and resource consuming and can divert a company’s

attention from the business.

International

Data Collection

contract research organizations (“CROs”) and clinical investigators involved in our clinical trials may collect,

receive, store, process, use, generate, transfer, disclose, make accessible, protect, secure, dispose of, transmit and share

(collectively, “process”) personal data as defined in data protection laws, from individuals residing outside the U.S.

Accordingly, we are subject to numerous foreign privacy and security laws regulating the collection, use, safeguarding, transfer and

other processing of personal data.

virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must

For example, in the EU/EEA, we are subject to the EU General Data Protection Regulation (the “EU GDPR”), and

associated Data Protection Legislation, which govern the collection and use of personal data as it pertains to individuals residing

in the EU/EEA.

This legislation imposes several requirements, including, but not limited to:

determining the lawful bases of the processing

of personal data, providing transparency information to the affected individuals, managing contractual

relationships with relevant vendors and other third parties, notifying the appointment of a data protection officer to the relevant

EU/EEA/UK competent national data protection authorities, and ensuring the security and confidentiality of personal data.

The GDPR also

imposes strict rules on the transfer of personal data outside of the EU/EEA/UK to the U.S.

Failure to comply with the requirements of

the GDPR and the related national data protection laws of the EU/EEA Member States and the UK may result in administrative penalties and

other enforcement actions.

We have incurred, and expect to continue to incur, compliance expenses in connection with the GDPR.

found to be in violation of the GDPR, our product development timeline may be affected, which would potentially affect our ability to

generate revenue and might impact our competitive position.

Current and Future Legislation

and other jurisdictions, continued healthcare

reform measures may result in more rigorous coverage criteria and additional downward pressure on the price that we, or any collaborators,

providing information to individuals

regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data,

processing personal data only under one of the six lawful bases for processing, managing

contractual relationships with vendors and other third parties, and notifying the appointment of a data protection officer to

the relevant EU/EEA competent national data protection authorities.

The EU GDPR also imposes strict rules on the transfer of

personal data outside of the EU/EEA.

Personal data transferred to a jurisdiction outside the EU/EEA that does not provide adequate

protection for personal data (an “adequate jurisdiction”) must be protected by standard contractual clauses (a standard

form of contract approved by the European Commission).

Currently, the U.S.

is only an adequate jurisdiction for companies that

certify to the EU-U.S.

Data Privacy Framework.

As we are not certified to the EU-U.S.

Data Privacy Framework, we must rely on

standard contractual clauses and other Article 45 protections when transferring personal data from the EU/EEA to the U.S.

that must comply with the EU GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of

data protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenue of

the noncompliant company, whichever is greater.

The EU GDPR also confers a private right of action in some circumstances on data

subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation

for damages resulting from violations of the EU GDPR.

We have incurred, and expect to continue to incur, compliance expenses in

connection with the EU GDPR.

If we are found to be in violation of the EU GDPR, our product development timeline may be affected,

which would potentially affect our ability to generate revenue and might impact our competitive position.

following the withdrawal of the United Kingdom from the EU, we have to comply with the GDPR as implemented in the United Kingdom (the

The UK GDPR penalty structure mirrors the EU GDPR and has the ability to fine up to the greater of €20 million/£17

million or 4% of global turnover.

The European Commission has adopted an adequacy decision in favor of the United Kingdom, enabling data

transfers from European Union member states to the United Kingdom without additional safeguards.

However, the framework for transfer

of personal data from the UK to jurisdictions outside the UK, EU, or EEA is different from the EU GDPR.

The UK has implemented its own

standard contractual clauses to protect UK personal data transferred to countries that are not adequate jurisdictions.

and Future Legislation

and other jurisdictions, continued healthcare reform measures may result in more rigorous coverage criteria and additional downward

pressure on the price that we, or any collaborators, may receive.

Individual states in the U.S.

have also been increasingly passing legislation and implementing regulations designed to control

pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain

product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other

countries and bulk purchasing.

Regulations may also prevent or delay marketing approval of our product candidates, restrict or regulate

post-approval activities and affect our ability to profitably sell any product candidates.

Other Regulatory Requirements

Our operations use small amounts of hazardous materials

in research and development and generate regulated medical waste in the normal course of performing our CELsignia tests.

This subjects

us to a variety of federal, state and local environmental and safety laws and regulations.

Some of the regulations under the current regulatory

structure provide for strict liability, holding a party potentially liable without regard to fault or negligence.

We could be held liable

for damages and fines as a result of our, or others’, business operations should contamination of the environment or individual

exposure to hazardous substances occur.

We cannot predict how changes in laws or development of new regulations will affect our business

operations or the cost of compliance.

Impact of Public Health Matters on our Business

As witnessed during the COVID-19 pandemic, future

outbreaks or variants of the virus or other public health disruptions may cause additional delays in our clinical trial work or impact

our ability to access health care practitioners who might utilize our product.

Corporate History

We were organized as a Minnesota limited liability

company in 2011 and commenced operations in 2012.

On September 15, 2017, we converted from a Minnesota limited liability company

into a Delaware corporation and changed our name from Celcuity LLC to Celcuity Inc.

Employees and Labor Relations

As of December 31, 2024, we had 87 full-time

employees, most of which were engaged in research and development activities, though hiring employees in preparation for anticipated commercial

launch has begun.

None of our employees are currently represented by a labor union or covered by a collective bargaining agreement and

we believe that our relations with our employees are good.

During 2024, our voluntary turnover rate was approximately 5%.

have also been increasingly passing legislation

and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement

constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some

cases, designed to encourage importation from other countries and bulk purchasing.

Regulations may also prevent or delay marketing approval

of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates.

Regulatory Requirements

operations use small amounts of hazardous materials in research and development and generate regulated medical waste in the normal course

of performing our laboratory tests.

This subjects us to a variety of federal, state and local environmental and safety laws and regulations.

Some of the regulations under the current regulatory structure provide for strict liability, holding a party potentially liable without

regard to fault or negligence.

We could be held liable for damages and fines as a result of our, or others’, business operations

should contamination of the environment or individual exposure to hazardous substances occur.

We cannot predict how changes in laws or

development of new regulations will affect our business operations or the cost of compliance.

were organized as a Minnesota limited liability company in 2011 and commenced operations in 2012.

On September 15, 2017, we converted

from a Minnesota limited liability company into a Delaware corporation and changed our name from Celcuity LLC to Celcuity Inc.

and Labor Relations

of December 31, 2025, we had 155 full-time employees, most of which were engaged in research and development activities, though hiring

employees in preparation for anticipated commercial launch has begun.

None of our employees are currently represented by a labor union

or covered by a collective bargaining agreement and we believe that our relations with our employees are good.

During 2025, our voluntary

turnover rate was approximately 4%.

About Our Executive Officers

following table sets forth information concerning our executive officers.

Executive Officer and Chairman of the Board

Science Officer, Vice President, Secretary and Director

Financial Officer

Sullivan is our co-founder and has served as Chairman of the Board and Chief Executive Officer since we commenced operations in

Sullivan has over 30 years of experience founding and building successful, high-growth technology companies.

He was Chairman

and CEO of SterilMed, a medical device reprocessing company, from 2003, when he led an investment group to acquire a majority interest,

until its sale to Ethicon Endo-Surgery Inc., a Johnson & Johnson company, for $330 million in 2011.

Previously, he was co-founder

and Chief Executive Officer of Recovery Engineering, a filtration company, which he took public and subsequently sold to Procter &

Gamble for $265 million in 1999.

Sullivan previously served on the board of directors of two publicly-held companies, Entegris, Inc.

and Virtual Radiologic Inc.

Sullivan has received nine U.S.

patents and has several patents pending.

He graduated magna cum laude

with distinction from Harvard College with an A.B.

in economics.

is our co-Founder and has served as Chief Science Officer, Vice President, Secretary and a director since we

commenced operations in 2012.

Laing’s career spans more than 20 years in drug discovery research and technology

He received his doctorate in biophysics and biochemistry from The Johns Hopkins University and completed a National

Institutes of Health post-doctoral fellowship at Washington University Medical School in biophysics.

He has received 27 U.S.

and has several U.S.

patents pending.

His drug discovery research career began at Scriptgen/Anadys Pharmaceuticals (purchased

by Novartis), where he worked under Professor Peter Kim.

He also was Director of Chemistry and Bioapplications and Director of

Detection Product Development for two companies that each developed instruments similar to those used by Celcuity.

His work at these

two instrument companies gave him unique expertise and experience in developing a variety of patented applications for these

Most recently, he served as an executive director for an international drug discovery and development

Hahne joined as our Chief Financial Officer in July 2017.

She has more than 25 years of financial leadership experience, including

the most recent 20 years in the healthcare industry.

Prior to joining Celcuity, Ms.

Hahne served as Controller of Respiratory Technologies

Inc., a medical device manufacturer, from 2015 to 2017.

While at Respiratory Technologies, she played a key role in the due diligence

process to sell the company to Koninklijke Philips.

In 2014, she served as Controller for Ability Network Inc., a healthcare information

technology company.

From 2007 to 2012, Ms.

Hahne served as Controller of SterilMed Inc., a medical device reprocessing company, where

she was significantly involved in the sale of the company to Johnson & Johnson.

Prior to these roles, Ms.

Hahne held several senior

financial positions at SimonDelivers Inc., including Chief Financial Officer.

Hahne has extensive experience in early stage, high

growth companies with responsibilities including financial controls and stewardship, financial analysis, mergers and acquisitions, building

infrastructure and systems.

She received a B.S.

degree in Finance and Accounting from Northern State University and received her CPA

certificate in 1990.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business